2013-05-10T14:44:00-05:00 2012-06-30 911194016 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1700 BELLEVUE WA 98004 990 2011-07-01 237156071 FRED HUTCHINSON CANCER RESEARCH CENTER FRED 2066674876 1100 FAIRVIEW AVENUE NORTH SEATTLE WA 981091024 RANDALL C MAIN 2066674876 2013-05-10 1 SARA ELIZABETH J HYRE P00235495 4254544919 2011 2016-02-24 21:20:13Z LAWRENCE COREY 1100 FAIRVIEW AVENUE NORTH SEATTLE WA 981091024 523405356 0 X WWW.FHCRC.ORG X 1971 WA THE ELIMINATION OF CANCER AND RELATED DISEASES AS CAUSES OF HUMAN SUFFERING AND DEATH. 18 17 3132 400 0 -37143 388454000 369203443 51692311 59744175 9756524 4138847 20703489 9290457 470606324 442376922 80189368 79888530 0 0 214220175 224888268 59204 83076 6913589 131738614 131299306 426207361 436159180 44398963 6217742 714148481 714068907 461116144 481168125 253032337 232900782 X FRED HUTCHINSON CANCER RESEARCH CENTER'S (THE CENTER) MISSION IS THE ELIMINATION OF CANCER AND RELATED DISEASES AS CAUSES OF HUMAN SUFFERING AND DEATH. THE CENTER CONDUCTS RESEARCH TO IMPROVE PREVENTION AND TREATMENT OF CANCER AND RELATED DISEASES. 0 0 134810746 44670654 19609323 VACCINE AND INFECTIOUS DISEASE DIVISION:THE VACCINE AND INFECTIOUS DISEASE DIVISION, VIDD, WAS ESTABLISHED BY THE FRED HUTCHINSON CANCER RESEARCH CENTER, FIRST AS AN INSTITUTE IN 2007 AND AS A SCIENTIFIC DIVISION OF THE CENTER IN 2010, TO ADDRESS THE GROWING NEED FOR TREATMENT AND PREVENTION STRATEGIES FOR INFECTIOUS DISEASES WORLDWIDE. BY INTEGRATING BIOMETRIC, LABORATORY, AND CLINICAL SCIENCE, THE RESEARCHERS AT VIDD AIM TO DEVELOP NOVEL VACCINES FOR INFECTIOUS DISEASES THAT THREATEN GLOBAL HEALTH, TO SHED LIGHT ON THE WORKINGS OF THE HUMAN IMMUNE SYSTEM, AND TO DEVELOP NOVEL TREATMENT AND PREVENTION STRATEGIES TO LESSEN THE BURDEN OF INFECTIOUS DISEASES AND CANCERS CAUSED BY INFECTION, PARTICULARLY IN THE IMMUNOCOMPROMISED HOST. 114559825 22039124 16663661 PUBLIC HEALTH SCIENCES DIVISION: THE GOAL OF THE PUBLIC HEALTH SCIENCES DIVISION IS TO IDENTIFY STRATEGIES THAT WOULD ULTIMATELY REDUCE THE INCIDENCE OF AND MORTALITY FROM CANCER AND OTHER DISEASES. THE PUBLIC HEALTH SCIENCES DIVISION IS MADE UP OF SIX MAJOR PROGRAMS: BIOSTATISTICS & BIOMATHEMATICS, CANCER PREVENTION, COMPUTATIONAL BIOLOGY, EPIDEMIOLOGY, AND TRANSLATIONAL RESEARCH. 99963257 7438090 14540471 CLINICAL RESEARCH DIVISION: FROM LABORATORY BENCH TO BEDSIDE, THE CLINICAL RESEARCH DIVISION WORKS TO DEVELOP AND ANALYZE NEW TREATMENTS FOR CANCERS AND OTHER DISEASES. 31279005 4839183 4549786 HUMAN BIOLOGY DIVISION:THE MISSION OF THE HUMAN BIOLOGY DIVISION IS TO CULTIVATE INTERDISCIPLINARY RESEARCH TO ADVANCE UNDERSTANDING OF HUMAN BIOLOGY AND THE COMPLEX PROBLEMS OF NEOPLASIA AND OTHER HUMAN DISEASES. THE DIVISION IS STRUCTURED TO FOSTER LABORATORY-BASED AND COMPUTATIONAL RESEARCH AT THE INTERFACE OF BASIC, CLINICAL, AND POPULATION SCIENCES. DENISE GALLOWAY IS THE INTERIM DIRECTOR OF HUMAN BIOLOGY. 30118171 901479 4380934 BASIC SCIENCES DIVISION: THE BASIC SCIENCES DIVISION AT THE FRED HUTCHINSON CANCER RESEARCH CENTER WAS FOUNDED IN 1981 WITH THE GOAL OF PROVIDING A UNIQUE AND EXCITING ENVIRONMENT TO FOSTER CREATIVE AND GROUNDBREAKING RESEARCH. THE DIVISION CONSISTS OF 27 LABORATORIES, EACH WORKING IN DIVERSE AREAS RELATED TO ALL ASPECTS OF BIOLOGY. THE LABS EMPLOY STRUCTURAL, GENETIC, MOLECULAR, CELLULAR, DEVELOPMENTAL, AND EVOLUTIONARY BIOLOGY METHODS TO ADDRESS UNRESOLVED QUESTIONS IN BIOLOGY USING A WIDE RANGE OF MODEL SYSTEMS. 61397176 5740662 8930720 410731004 1 1 0 1 0 0 0 1 0 1 1 1 1 0 1 0 0 1 0 0 1 1 0 1 1 1 0 1 0 1 1 0 1 0 0 0 0 0 0 0 1 1 1 0 0 0 1 1 0 0 0 1 546 0 1 3132 1 0 1 UG 0 0 0 1 1 0 0 0 0 X 18 17 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AR AZ CA CO CT FL GA HI IL KS KY MA MD ME MI MN MO MS NC ND NH NJ NM NY OH OK OR PA RI SC TN UT VA WA WI WV X RANDALL C MAIN 2066674876 1100 FAIRVIEW AVENUE NORTH SEATTLE WA 981091024 STEVE DAVIS 5.00 X X 0 0 0 DOUGLAS WILLIAMS 3.00 X X 0 0 0 RICHARD ANDERSON 3.00 X X 0 0 0 KARL EGE 6.00 X X 0 0 0 HOLLIS DILLON 1.00 X 0 0 0 KAREN GLOVER 2.00 X 0 0 0 STEPHEN GRAHAM 1.00 X 0 0 0 RONALD HOWELL 1.00 X 0 0 0 HENRY JAMES 1.00 X 0 0 0 RICHARD MCCUNE 2.00 X 0 0 0 ROBERT NELSEN 1.00 X 0 0 0 PETER NEUPERT 1.00 X 0 0 0 CHARLES NOLAN 3.00 X 0 0 0 PAULA REYNOLDS 3.00 X 0 0 0 JAMES SINEGAL 1.00 X 0 0 0 VIJAY VASHEE 1.50 X 0 0 0 DOUGLAS WALKER 6.00 X 0 0 0 RICK KOFFEY 5.00 X 0 0 0 LAWRENCE COREY MD 40.00 X 779106 0 45396 FREDERICK R APPELBAUM MD 40.00 X 637779 0 44646 JANELL E BALDWIN 40.00 X 223707 0 36040 ANTHONY J BOZZUTI 40.00 X 280412 0 48361 JONATHAN A COOPER PHD 40.00 X 282131 0 42684 SUSAN C DOLBERT PHD 40.00 X 183580 0 3060 LINDA L GAINER 40.00 X 248902 0 39739 DENISE GALLOWAY PHD 40.00 X 280411 0 43604 MARK T GROUDINE MD PHD 40.00 X 537578 0 45318 RANDALL C MAIN 40.00 X 389545 0 45222 MARGARET JULIANA MCELRATH MD PHD 40.00 X 312402 0 43008 ULRICH W MUELLER PHD 40.00 X 264166 0 48244 HOWARD ALBERT NACHTRIEB 40.00 X 248893 0 48138 ROSS L PRENTICE PHD 40.00 X 414412 0 45279 SCOTT N RUSCH 40.00 X 206791 0 39762 DOUGLAS J SHAEFFER 40.00 X 335080 0 45507 MYRA H TANITA 40.00 X 489704 0 40138 STEVEN G SELF PHD 40.00 X 290841 0 44420 SAMIR M HANASH MD 40.00 X 337366 0 43774 MARTIN A CHEEVER MD 40.00 X 287195 0 41796 IRWIN D BERNSTEIN MD 40.00 X 307683 0 42614 JANET LEE STANFORD MD 40.00 X 266946 0 48447 BRIAN J REID MD 40.00 X 265064 0 44947 7869694 0 970144 345 0 1 0 SEATTLE CANCER CARE ALLIANCE 825 EASTLAKE AVE E SEATTLE WA 98109 PATIENT CARE SERVICES 1607937 METROPOLITAN BUILDING MAINTENANCE CO 3829 AURORA AVE N SEATTLE WA 98103 MAINTENANCE SERVICES 1278518 GREEN RUBINO 1938 FAIRVIEW AVE E STE 200 SEATTLE WA 98102 MARKETING SERVICES 1073452 BARC FIRST FLOOR NAPIE JOHANNESBURG WESTERN CAPE SF 2092 ZAF RESEARCH SERVICES 875442 UNIVERSITY OF CF 12424 RESEARCH PKWY SUITE 300 ORLANDO FL 328263249 RESEARCH SERVICES 826894 59 725880 4589884 328727322 35160357 6261189 369203443 INTERAFFILIATE AGMTS 541711 36737557 36737557 RESEARCH ACTIVITIES 541711 12467368 12467368 PATIENT SVCS AT SCCA 622110 10539250 10539250 59744175 3866859 3866859 250515 250515 6511134 6511134 3314050 0 3314050 3314050 3314050 79618000 43148 79639675 0 -21675 43148 21473 21473 771977 4589884 1375259 -603282 -603282 82055 13500 68555 68555 442376922 59744175 0 13429304 72416568 72416568 7471962 7471962 7369222 3753854 3245465 369903 171696733 137705120 30468184 3523429 12717391 10337108 2101343 278940 19854451 16072805 3347817 433829 13250471 10591228 2379315 279928 1371466 14948 1356518 275916 14126 261790 140528 140528 83076 83076 666607 666607 27081720 11729519 14645253 706948 392748 320523 72225 3308024 1605139 1543327 159558 2691966 2691966 11189330 171875 11017455 2857329 2193552 538069 125708 642839 531458 91199 20182 14126140 10591363 3534777 25736149 22641146 3095003 1537403 1537403 RESEARCH SUPPLIES 22316977 22316977 EQUIP. RENT & MAINT. 6440469 2476871 3899015 64583 ALLOC OF INDIRECT COSTS 0 70386976 -70386976 10523695 7708409 2020006 795280 436159180 410731004 18514587 6913589 9037 4275 61510742 32986577 34026493 30959498 18046009 17375292 621757 660124 1446837 1724061 680995194 324915036 325355893 356080158 125674643 99628066 40827536 62539963 71213967 77786370 2530782 2482655 32884785 31841868 714148481 714068907 35760069 41732382 26711012 31465334 372159052 367774147 26486011 40196262 461116144 481168125 X 162996337 141600782 38223000 38055000 51813000 53245000 253032337 232900782 714148481 714068907 X 6217742 -26349297 X 0 1 1 X 1 1 X 321146537 309432567 345330959 388454000 369203443 1733567506 321146537 309432567 345330959 388454000 369203443 1733567506 1733567506 14577277 21557624 17490065 24718143 13942558 92285667 990242 990242 1826843415 238056259 0.94890 0.94620 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 140528 140528 437255261 437395789 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 106714 112213 118859 140528 478314 250000 250000 250000 250000 1000000 1500000 0 0 0 0 732646 X X DONOR RESTRICTION 0 94229707 27184000 -2276000 0 1225000 0 117912707 82001707 14234000 14988000 0 16994000 0 94229707 75830000 5559524 7831043 0 7218860 0 82001707 100751000 4053000 -18913000 0 10061000 0 75830000 0.75000 0.22000 0.03000 0 0 52389138 52389138 380208685 190547015 189661670 172995992 134368021 38627971 75401379 75401379 356080158 MORTGAGE-BACKED SECURITIES 1841379 C COLLATERIZED MORTGAGE OBLIGATIONS 350914 C ASSET BACKED SECURITIES 366519 C HEDGE FUNDS 27660575 C LIMITED PARTNERSHIPS 24441227 C IKARIA STOCK 7879349 C 62539963 INVESTMENT IN SEATTLE CANCER CARE ALLIANCE 77786370 C 77786370 DEFERRED CREDIT ON CASH FLOW HEDGES 40196262 40196262 PART III, LINE 4: IN JANUARY 2010, THE QTIP TRUST OF THE 1993 KULLMAN FAMILY TRUST DONATED TO THE CENTER A COLLECTION OF FORTY BLACK AND WHITE PHOTOGRAPHS WHICH HAD AN APPRAISED VALUE OF $710,646 AT THE TIME OF THE DONATION. THE ARTWORK DONATION AGREEMENT REQUIRES THE CENTER TO DISPLAY THE ARTWORK AS A COLLECTION AT ITS MAIN CAMPUS IN SEATTLE, WASHINGTON FOR AT LEAST TWENTY YEARS. THE ARTWORK DONATION AGREEMENT STATES THAT "THE CENTER SHALL HAVE THE RIGHT TO USE AND DISPLAY THE ARTWORK IN THE MANNER THAT BEST SERVES THE INTEREST OF THE CENTER." AT THE END OF THE REQUIRED TWENTY YEAR DISPLAY PERIOD, THE CENTER WILL DETERMINE IF OPPORTUNITIES EXIST THAT MAY ALLOW THE VALUE OF THE DONATED ARTWORK TO FUND THE CENTER'S RESEARCH. DESCRIPTION OF INTENDED USE OF ENDOWMENT FUNDS: PART V, LINE 4: THE CENTER'S SPENDING POLICY FOR ENDOWMENT FUNDS IS TO APPROPRIATE FOR DISTRIBUTION EACH YEAR 5% OF THE ENDOWMENT FUND'S AVERAGE FAIR VALUE OVER THE PRIOR THREE YEARS, PROVIDED THAT THE FAIR VALUE OF THE ENDOWMENT FUND EXCEEDS THE CORPUS. FOR A PORTION OF THE CENTER'S BOARD-DESIGNATED INVESTMENTS, THE CENTER DOES NOT APPROPRIATE FOR DISTRIBUTION ANY AMOUNT OF INVESTMENT RETURN AS ALL OF THE RETURN EARNED IS HELD TO GROW THE FUND FOR FUTURE REPAYMENT OF LONG-TERM DEBT. FOR THE REMAINING BOARD DESIGNATED INVESTMENTS, THE CENTER MAKES ALL INVESTMENT RETURN AVAILABLE FOR EXPENDITURE ON PROGRAMMATIC INITIATIVES. IN ESTABLISHING THESE POLICIES, THE CENTER CONSIDERED THE LONG-TERM EXPECTED RETURNS ON ITS ENDOWMENT AND BOARD-DESIGNATED INVESTMENTS. 1 CENTRAL AMERICA AND THE CARIBBEAN 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 429000 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 747000 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 1394000 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 10000 NORTH AMERICA 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 1424000 RUSSIA & THE NEWLY INDEPENDENT STATES 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 9000 SOUTH AMERICA 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 520000 SOUTH ASIA 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 18000 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 2920000 EAST ASIA AND THE PACIFIC - 0 0 PROGRAM SERVICES RESEARCH SERVICES 38000 EUROPE (INCLUDING ICELAND & GREENLAND) - 0 0 PROGRAM SERVICES RESEARCH SERVICES 352000 NORTH AMERICA - CANADA AND MEXICO, BUT 0 0 PROGRAM SERVICES RESEARCH SERVICES 714000 SUB-SAHARAN AFRICA - ANGOLA, 0 0 PROGRAM SERVICES RESEARCH SERVICES 705000 0 0 0 0 0 0 4551000 4729000 9280000 SOUTH AMERICA HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL 369130 WIRE SUB-SAHARAN AFRICA HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL 396882 WIRE NORTH AMERICA THE STATISTICAL AND COMPUTATIONAL ANALYSIS OF FLOW CYTOM 81421 CHECK NORTH AMERICA LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: MICRO 40481 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL 339991 WIRE EUROPE (INCLUDING ICELAND & GREENLAND) HPTN SDMC: LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORK 200324 WIRE SUB-SAHARAN AFRICA HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL 815852 WIRE EUROPE (INCLUDING ICELAND & GREENLAND) MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, 259665 WIRE SOUTH AMERICA HIV TESTING AND TREATMENT TO PREVENT ONWARD HIV TRANSMIS 27728 WIRE SOUTH AMERICA HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL 29268 WIRE EUROPE (INCLUDING ICELAND & GREENLAND) A PROSPECTIVE STUDY OF COLORECTAL CANCER: ONE-CARBON ME 95601 WIRE SOUTH AMERICA HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL 5213 WIRE EUROPE (INCLUDING ICELAND & GREENLAND) THE PATHOGENESIS OF FMD: FACIOSCAPULOHUMERAL MUSCULAR 252929 WIRE CENTRAL AMERICA AND THE CARIBBEAN HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL 326838 WIRE NORTH AMERICA BHGI INTERNATIONAL LEARNING LABORATORIES 75000 WIRE NORTH AMERICA COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSOR 273687 CHECK EAST ASIA AND THE PACIFIC BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI 689327 WIRE NORTH AMERICA A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE L 24456 CHECK SOUTH AMERICA DYNAMICS OF GRADIENT SENSING IN SINGLE CELLS 67508 WIRE CENTRAL AMERICA AND THE CARIBBEAN HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL 102246 WIRE NORTH AMERICA EXPANSION OF CARDIAC AND HEMATOPOIETIC PREGENITORS BY WN 159116 CHECK NORTH AMERICA EVALUATION OF A HEPATITIS B OUTREACH INTERVENTION FOR CA 55210 CHECK NORTH AMERICA THE GENETICS OF PARALLEL REPRODUCTIVE ISOLATION IN STICK 217836 CHECK SUB-SAHARAN AFRICA HVTN LABORATORY PROGRAM 232287 WIRE EUROPE (INCLUDING ICELAND & GREENLAND) IMMUNOBIOLOGY OF TOLERANCE FAHCT 16000 WIRE SUB-SAHARAN AFRICA HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL 13500 WIRE EUROPE (INCLUDING ICELAND & GREENLAND) BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI 18115 WIRE SUB-SAHARAN AFRICA HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL 7842 WIRE NORTH AMERICA HVTN LABORATORY PROGRAM 163992 CHECK SUB-SAHARAN AFRICA EARLY AND REINFECTION IN HIGH RISK WOMEN 29146 WIRE NORTH AMERICA HVTN LABORATORY PROGRAM 6359 CHECK NORTH AMERICA WASHINGTON VACCINE ALLIANCE 122527 CHECK SUB-SAHARAN AFRICA HVTN LABORATORY PROGRAM 1226344 WIRE 1 33 1 0 1 0 0 0 PROCEDURE FOR MONITORING GRANTS OUTSIDE THE U.S.: SCHEDULE F, PART I, LINE 2: ONCE THE NOTICE OF AWARD HAS BEEN RECEIVED AND THE CENTER PROJECT ID ACTIVATED, THE SUBAWARD CAN BE SET UP. THE STRUCTURE OF THE SUBAWARD WILL DEPEND ON HOW THE PRIME IS SET UP. GENERALLY AT THE CENTER, A NEW PO IS REQUISITIONED FOR EACH SUBAWARD FOR EACH YEAR OF A PROJECT. THIS ALLOWS THE RESEARCH COORDINATOR (RC) TO CLOSELY MONITOR SUBAWARD INVOICES AND ENCUMBRANCES. FOR OUR SUBRECIPIENTS, IT MEANS A SEPARATE BUDGET ID AND FINAL INVOICE EACH YEAR. CARRYOVER BETWEEN YEARS IS NOT AUTOMATIC. THERE ARE 5 PRIMARY STEPS: 1) STEP ONE IS WITHIN OSR. THE GRANT SPECIALIST NOTIFIES THE CONTRACT SPECIALIST THAT A GRANT WHICH INCLUDES A SUBAWARD HAS BEEN FUNDED AND PROVIDES TO THE CONTRACT SPECIALIST A COPY OF THE AWARD, THE SIGNED SUBAWARD APPLICATION (IF AVAILABLE) AND ANY SPECIAL INSTRUCTIONS. A SIGNED SUBAWARD APPLICATION IS IMPORTANT BECAUSE IT SHOWS THAT THE SUBRECIPIENT ORGANIZATION HAS REVIEWED AND APPROVED THE BUDGET AND SCOPE OF WORK. 2) THE RC SENDS THE CONTRACT SPECIALIST A SUBCONTRACT ACUISITION FORM (SAF). THIS FORM PROVIDES AUTHORIZATION FOR THE CONTRACT SPECIALIST TO ISSUE THE SUBAWARD. INCLUDED IN THIS FORM IS A SCOPE OF WORK, BUDGET AND PERTINENT SUBRECIPIENT INFORMATION. IT IS NECESSARY TO PROVIDE THE SCOPE OF WORK AND BUDGET ON THE SAF AS THESE TIMES MAY HAVE CHANGED FROM WHAT WAS ORIGINALLY SUBMITTED IN THE SUBAWARD APPLICATION. 3) THE CONTRACT SPECIALIST REQUISITIONS THE SUBAWARD PO, WHICH THE RC MUST APPROVE. AN EMAIL IS SENT TO THE RC NOTIFYING THEM THAT THE REQUISITION IS PENDING AND REQUIRES APPROVAL. BECAUSE OSR DOES NOT HAVE FUNDS COMMITMENT AUTHORITY THE RC IS REQUIRED TO APPROVE ALL REQUISITIONS. 4) OSR COLLECTS INFORMATION REQUIRED TO CORRECTLY SET UP THE SUBAWARD. THESE ITEMS INCLUDE IRO AND IACUC APPROVAL DATES, CONFIRMATION OF SUBAWARD F&A RATES AND A-133 AUDIT REPORTS, REVIEW OF PRIME SPECIAL TERMS AND CONDITIONS TO DETERMINE FLOW-DOWN, CONFIRMATION THAT THE SUBRECIPIENT IS NOT DEBARRED, AND OTHER SIMILAR REGULATORY AND ADMINISTRATIVE REQUIREMENTS. WHILE MUCH OF THIS INFORMATION IS COLLECTED BY OSR, THE RC MAY, IN ADDITION TO COMPLETING THE SAF, BE ASKED TO ASSIST IN THE COLLECTION OF SOME OF THE DOCUMENTATION. 5) OSR WRITES THE SUBAWARD AGREEMENT, AND MAILS IT TO THE SUBRECIPIENT FOR SIGNATURE. SOME AGREEMENTS CAN BE SIGNED BY OSR BEFORE MAILING, WHILE OTHERS WILL BE SENT UNSIGNED. THIS IS DETERMINED BY THE CONTRACT SPECIALIST BASED ON THE TERMS OF AWARD AND STATUS OF ADMINISTRATIVE AND REGULATORY REQUIREMENTS. A COPY OF THE INITIAL SUBAWARD IS SENT THE RC. ONCE THE SUBAWARD HAS BEEN FULLY SIGNED, A COPY IS SENT TO THE RC FOR THEIR FILES. NO INVOICES SHOULD BE APPROVED BY THE RC UNTIL THEY HAVE RECEIVED A FULLY EXECUTED AGREEMENT. METHOD USED TO ACCCOUNT FOR EXPENDITURES: SCHEDULE F, PART I, LINE 3: THE ACCRUAL METHOD WAS USED IN ACCOUNTING FOR EXPENDITURES IN PARTS I AND II. X X X X X X X 1 SEE PART IV P O BOX 3257 PORTLAND OR 97208 DIRECT MAIL 0 629059 64006 565053 SEE PART IV 1511 ROUTE 22 SUITE C-25 BREWSTER NY 10509 TELEMARKETING 0 22065 19070 2995 651124 83076 568048 AK AL AR AZ CA CO CT FL GA HI IL KS KY ND NC MS MO MN MI ME MD MA OR OK OH NY NM NJ NH UT TN SC RI PA WV WI WA VA HOLIDAY AUCTION 3390624 2883712 506912 172910 1924 598276 CLIMB FOR CANCER 608034 607234 800 320657 6 1363203 1098938 264265 51228 30000 200264 5361861 4589884 771977 224138 31924 1119197 1375259 -603282 82055 13500 1 0.95000 82055 13500 13500 68555 WA 1 0 1 0 0.00000 1.00000 ACCOUNTING DEPARTMENT 1100 FAIRVIEW AVENUE NORTH SEATTLE WA 98109 0 KRISTEN SCHERRER 5000 PLANNING RAFFLE, PROCURING PRIZES, AND COORDINATING WITH VOLUNTEERS. X 0 0 SCHEDULE G, PART I, LINE 2B, LIST OF TEN HIGHEST PAID FUNDRAISERS: (I) NAME OF FUNDRAISER: LEWIS KENNEDY ASSOCIATES INC (I) ADDRESS OF FUNDRAISER: PO BOX 3257 PORTLAND, OR 97208 (I) NAME OF FUNDRAISER: HARRIS CONNECT GROUP HOLDINGS LLC (I) ADDRESS OF FUNDRAISER: 1511 ROUTE 22, SUITE C-25 BREWSTER, NY 10509 1 ADMINISTRATORS OF THE TULANE 800 E COMMERCE RD SUITE 203 HARAHAN LA 70123 720423889 501(C)(3) 31005 HVTN LABORATORY PROGRAM AIDS RESEARCH ALLIANCE OF AMERICA 1400 S GRAND AVE SUITE 701 LOS ANGELES CA 90015 954264845 501(C)(3) 783190 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL ALERE WELLBEING INC P O BOX 402617 ATLANTA GA 303842617 200231080 33760 IMPROVING SMOKING CESSATION QUITLINES BATTELLE MEMORIAL INSTITUTE 1100 DEXTER AVE NORTH SUITE 400 SEATTLE WA 981093598 314379427 501(C)(3) 81626 IMPROVING EARLY DETECTION OF BREAST CANCER BATTELLE MEMORIAL INSTITUTE 1100 DEXTER AVE NORTH SUITE 400 SEATTLE WA 981093598 314379427 501(C)(3) 9390 RADIATION DOSE-DEPENDENT INTERVENTIONS BATTELLE MEMORIAL INSTITUTE PACIFIC NW NATIONAL LABORATORY RICHLAND WA 99352 314379427 501(C)(3) 2956 TARGETED RADIOTHERAPY WITH 90Y-BC8 MONOCLONAL ANTIBODY BATTELLE MEMORIAL INSTITUTE 1100 DEXTER AVE NORTH SUITE 400 SEATTLE WA 981093598 314379427 501(C)(3) 45175 THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA ROOM BCM280 HOUSTON TX 77030 741613878 501(C)(3) 324712 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL BAYLOR COLLEGE OF MEDICINE P O BOX 201361 HOUSTON TX 772161361 741613878 501(C)(3) 20071 PEDIATRIC GLIOBLASTOMA THERAPIES BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE 1500 E DUARTE RD DUARTE CA 910103012 953432210 501(C)(3) 35819 BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTIBILITY BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE 1500 E DUARTE RD DUARTE CA 910103010 953432210 501(C)(3) 8455 CTRIP: NOTCH-MEDIATED EXPANSION OF CORD BLOOD PROGENITOR BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE 1500 E DUARTE RD DUARTE CA 910103012 953432210 501(C)(3) 90814 TARGETED MODIFICATION OF HOST AND PROVIRAL DNA BENAROYA RESEARCH INSTITUTE 1201 NINTH AVENUE SEATTLE WA 98101 910653422 501(C)(3) 1724 CORE CENTER OF EXCELLENCE IN HEMATOLOGY BENAROYA RESEARCH INSTITUTE 1201 NINTH AVENUE SEATTLE WA 98101 910653422 501(C)(3) 33001 HEMATOPOIETIC CELL TRANSPLANTATION AND IRON OVERLOAD BENAROYA RESEARCH INSTITUTE 1201 NINTH AVENUE SEATTLE WA 98101 910653422 501(C)(3) 79854 MIXED HEMATOPOIETIC CHIMERISM AFTER STEM CELL ALLOGRAFTS BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501(C)(3) 16455 HVTN LABORATORY PROGRAM BOARD OF TRUSTEES OF THE LELAND STANFORD JR UNIVERSITY P O BOX 44253 SAN FRANCISCO CA 941444253 941156365 501(C)(3) 50793 CANCER CENTER SUPPORT GRANT (COMPREHENSIVE) BOARD OF TRUSTEES OF THE LELAND STANFORD JR UNIVERSITY P O BOX 44253 SAN FRANCISCO CA 941444253 941156365 501(C)(3) 33279 IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC BOARD OF TRUSTEES OF THE LELAND STANFORD JR UNIVERSITY P O BOX 44253 SAN FRANCISCO CA 941444253 941156365 501(C)(3) 35336 IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GVHD BOARD OF TRUSTEES OF THE LELAND STANFORD JR UNIVERSITY P O BOX 44253 SAN FRANCISCO CA 941444253 941156365 501(C)(3) 47979 OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH BOARD OF TRUSTEES OF THE LELAND STANFORD JR UNIVERSITY P O BOX 44253 SAN FRANCISCO CA 941444253 941156365 501(C)(3) 126864 PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM BOARD OF TRUSTEES UNIVERSITY OF ILLINOIS P O BOX 20787 SPRINGFIELD IL 627080787 376000511 UNIVERSITY 52485 HVTN LABORATORY PROGRAM BOARD OF TRUSTEES UNIVERSITY OF ILLINOIS P O BOX 20787 SPRINGFIELD IL 627080787 376000511 UNIVERSITY 896343 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL BRIGHAM AND WOMENS HOSPITAL INC FINANCE P O BOX 3887 BOSTON MA 022413887 402312909 501(C)(3) 69693 BARRETT'S ESOPHAGUS: PREDICTORS OF PROGRESSION BRIGHAM AND WOMENS HOSPITAL INC FINANCE P O BOX 3887 BOSTON MA 022413887 402312909 501(C)(3) 38918 BIOCONDUCTOR: AN OPEN COMPUTING RESOURCE FOR GENOMICS BRIGHAM AND WOMENS HOSPITAL INC FINANCE P O BOX 3887 BOSTON MA 022413887 402312909 501(C)(3) 70605 BIOCONDUCTOR: AN OPEN COMPUTING RESOURCE FOR GENOMICS BRIGHAM AND WOMENS HOSPITAL INC FINANCE P O BOX 3887 BOSTON MA 022413887 402312909 501(C)(3) 179457 COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES BRIGHAM AND WOMENS HOSPITAL INC FINANCE P O BOX 3887 BOSTON MA 022413887 402312909 501(C)(3) 656915 GENOME-WIDE ASSOCIATION STUDY OF NONSYNONYMOUS SNPS BRIGHAM AND WOMENS HOSPITAL INC FINANCE P O BOX 3887 BOSTON MA 022413887 402312909 501(C)(3) 914889 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL BRIGHAM AND WOMENS HOSPITAL INC FINANCE P O BOX 3887 BOSTON MA 022413887 402312909 501(C)(3) 47615 OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH BROAD INSTITUTE INC 7 CAMBRIDGE CENTER CAMBRIDGE MA 02142 263428781 501(C)(3) 14975 BREAST CANCER BIOMARKER DISCOVERY CONSORTIUM BROAD INSTITUTE INC 7 CAMBRIDGE CENTER CAMBRIDGE MA 02142 263428781 501(C)(3) 359672 GENOME-WIDE ASSOCIATION STUDY OF NONSYNONYMOUS SNPS BROAD INSTITUTE INC 7 CAMBRIDGE CENTER CAMBRIDGE MA 02142 263428781 501(C)(3) 562474 IMPROVING EARLY DETECTION OF BREAST CANCER BROAD INSTITUTE INC 7 CAMBRIDGE CENTER CAMBRIDGE MA 02142 263428781 501(C)(3) 945127 MEASUREMENT OF CANCER-ASSOCIATED BIOMARKER PROTEINS IN C BROAD INSTITUTE INC 7 CAMBRIDGE CENTER CAMBRIDGE MA 02142 263428781 501(C)(3) 53481 THE BREAST CANCER BIOMARKER DISCOVERY CONSORTIUM CALIFORNIA RURAL INDIAN HEALTH BOARD INC 4400 AUBURN BLVD 2ND FLOOR SACRAMENTO CA 95841 237052541 501(C)(3) 25832 A MULTI-STATE STUDY OF CANCER TREATMENT AND OUTCOME AMON CANCER RESEARCH AND BIOSTATISTICS 1730 MINOR AVENUE SUITE 1900 SEATTLE WA 981011468 911828539 501(C)(3) 225590 CENTER FOR COMPARATIVE EFFECTIVENESS RESEARCH IN CANCER CANCER RESEARCH AND BIOSTATISTICS 1730 MINOR AVENUE SUITE 1900 SEATTLE WA 981011468 911828539 501(C)(3) 2983728 SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVENUE CLEVELAND OH 441067037 341018992 501(C)(3) 480394 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVENUE CLEVELAND OH 441067037 341018992 501(C)(3) 313267 IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS CEDARS SINAI MEDICAL CENTER 6500 WILSHIRE BLVD SUITE 1150 LOS ANGELES CA 90048 951644600 501(C)(3) 8254 IN VIVO EFFECTS OF SULFORAPHANE SUPPLEMENTATION CEDARS SINAI MEDICAL CENTER 6500 WILSHIRE BLVD SUITE 1150 LOS ANGELES CA 90048 951644600 501(C)(3) 173432 PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM CEDARS SINAI MEDICAL CENTER 6500 WILSHIRE BLVD SUITE 1150 LOS ANGELES CA 90048 951644600 501(C)(3) 3179 VITAMIN D AND PROSTATE CANCER: BIOMARKERS AND GENETIC CENTER FOR MEDICAL TECHNOLOGY POLICY 401 EAST PRATT ST SUITE 631 BALTIMORE MD 21202 261409553 501(C)(3) 144998 CENTER FOR COMPARATIVE EFFECTIVENESS RESEARCH IN CANCER CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI OH 452293039 310833936 501(C)(3) 41704 DEVELOPMENT OF SAFE AND EFFICIENT GENE THERAPY STRATEGIES CITY AND COUNTY OF SAN FRANCISCO 1380 HOWARD ST RM 408 SAN FRANCISCO CA 941032614 946000417 CITY-CNT OF SF 304913 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL CITY OF PHILADELPHIA 1401 JOHN KENNEDY BLVD SUITE 1380 PHILADELPHIA PA 19102 236003047 CITY OF PHILADELPHIA 229309 HPTN SDMC: LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORK CLINICAL ALLIANCE FOR RESEARCH AND EDUCATION 3289 WOODBURN RD SUITE 250 ANNANDALE VA 22003 202651141 221568 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL COMSYS INFO TECHNOLOGY SERVICES LLC P O BOX 905378 CHARLOTTE NC 282905378 751300240 347240 CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE CONCEPT SYSTEMS INCORPORATED 136 EAST STATE ST ITHACA NY 14850 161473796 72342 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL CORNELL UNIVERSITY P O BOX 22 ITHACA NY 148510022 150532082 501(C)(3) 63361 TOWARDS A MODEL OF FANCONI ANEMIA DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 501(C)(3) 5147 IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 501(C)(3) 60278 IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GVHD DISTRICT OF COLUMBIA GOV DC TREASURY 899 NORTH CAPITOL NE WASHINGTON DC 20002 536001131 DISTRICT OF COLUMBIA 416535 HPTN SDMC: LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORK DUKE UNIVERSITY 2200 W MAIN ST SUITE 300 DURHAM NC 277054677 560532129 501(C)(3) 2148189 HVTN LABORATORY PROGRAM DUKE UNIVERSITY 2200 W MAIN ST SUITE 300 DURHAM NC 277054677 560532129 501(C)(3) 61023 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL EMORY UNIVERSITY 1599 CLIFTON RD NE ATLANTA GA 303224250 580566256 501(C)(3) 169839 CONTAINING BIOTERRORISM AND EMERGING INFECTIOUS DISEASES EMORY UNIVERSITY 1599 CLIFTON RD NE ATLANTA GA 303224250 580566256 501(C)(3) 285039 HARNESSING INNATE IMMUNITY TO ENHANCE IMMUNOGENICITY EMORY UNIVERSITY 1599 CLIFTON RD NE ATLANTA GA 303224250 580566256 501(C)(3) 965927 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL EXAMINATION MANAGEMENT SERVICES INC P O BOX 202669 DALLAS TX 752302669 751444139 156144 CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE FENWAY COMMUNITY HEALTH 1340 BOYLSTON ST FINANCE 9TH FLOOR BOSTON MA 02215 042510564 501(C)(3) 478600 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL FENWAY COMMUNITY HEALTH 1340 BOYLSTON ST FINANCE 9TH FLOOR BOSTON MA 02215 042510564 501(C)(3) 12703 LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL FISHER BIOSERVICES P O BOX 418395 BOSTON MA 022418395 541348241 754114 CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE FRONTIER SCIENCE AND TECHNOLOGY P O BOX 983027 BOSTON MA 022983027 161056814 501(C)(3) 104762 HPTN SDMC: LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORK FRONTIER SCIENCE AND TECHNOLOGY P O BOX 983027 BOSTON MA 022983027 161056814 501(C)(3) 95803 HVTN LABORATORY PROGRAM FRONTIER SCIENCE AND TECHNOLOGY P O BOX 983027 BOSTON MA 022983027 161056814 501(C)(3) 48298 HVTN SDMC: LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORK FRONTIER SCIENCE AND TECHNOLOGY P O BOX 983027 BOSTON MA 022983027 161056814 501(C)(3) 42142 LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS FRONTIER SCIENCE AND TECHNOLOGY P O BOX 983027 BOSTON MA 022983027 161056814 501(C)(3) 44080 RAPID SCALEUP OF HIV/AIDS CARE AND TREATMENT SERVICES GENERAL HOSPITAL CORPORATION P O BOX 3829 BOSTON MA 022413829 042697983 501(C)(3) 202240 EXPANSION OF CARDIAC AND HEMATOPOIETIC PREGENITORS GENERAL HOSPITAL CORPORATION P O BOX 3829 BOSTON MA 022413829 042697983 501(C)(3) 45054 MEASUREMENT OF CANCER-ASSOCIATED BIOMARKER PROTEINS GENERAL HOSPITAL CORPORATION P O BOX 414876 BOSTON MA 022414876 042697983 501(C)(3) 165456 MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS GROUP HEALTH COOPERATIVE P O BOX 34587 SEATTLE WA 981249990 910511770 501(C)(3) 381746 ACCEPTANCE AND COMMITMENT THERAPY FOR SMOKING CESSATI GROUP HEALTH COOPERATIVE P O BOX 34587 SEATTLE WA 981249990 910511770 501(C)(3) 820480 MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS GROUP HEALTH COOPERATIVE P O BOX 34587 SEATTLE WA 981249990 910511770 501(C)(3) 6876 PREVENTION OF OVARIAN CANCER IN WOMEN H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 12902 MAGNOLIA DRIVE TAMPA FL 33612 593238634 501(C)(3) 30704 AFFINITY BASED STRATEGIES TO FAST TRACK DEVELOPMENT OF C H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 12902 MAGNOLIA DRIVE TAMPA FL 33612 593238634 501(C)(3) 51800 IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 12902 MAGNOLIA DRIVE TAMPA FL 33612 593238634 501(C)(3) 20488 IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GVHD HEKTOEN INSTITUTE FOR MED RESEARCH LLC 2240 W OGDEN AVE CHICAGO IL 606129982 362244897 501(C)(3) 133560 HPTN SDMC: LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORK HEMATOLOGICS INC P O BOX 24712 SEATTLE WA 98124 911685196 42400 BRIDGE FUNDING: MOLECULAR ASSESSMENT OF MINIMAL RISK DIS INDIANA UNIVERSITY P O BOX 66057 INDIANAPOLIS IN 462666057 356001673 UNIVERSITY 326018 MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS INFECTIOUS DISEASE CNSLTNTS MD PA DBA 1701 N MILLS AVE ORLANDO FL 32803 591634257 1418895 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL JOHNS HOPKINS UNIVERSITY 12529 COLLECTIONS CENTER DR CHICAGO IL 60693 520595110 501(C)(3) 12903 BIOCONDUCTOR: AN OPEN COMPUTING RESOURCE FOR GENOMICS JOHNS HOPKINS UNIVERSITY 12529 COLLECTIONS CENTER DR CHICAGO IL 60693 520595110 501(C)(3) 80474 BIOCONDUCTOR: AN OPEN COMPUTING RESOURCE FOR GENOMICS JOHNS HOPKINS UNIVERSITY 12529 COLLECTIONS CENTER DR CHICAGO IL 60693 520595110 501(C)(3) 9753 GENETIC PROGRESSION OF PANCREATIC MUCINOUS CYSTIC NEOPLA JOHNS HOPKINS UNIVERSITY 12529 COLLECTIONS CENTER DR CHICAGO IL 60693 520595110 501(C)(3) 37195 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL KAISER FOUNDATION HOSPITALS 1800 HARRISON ST 16TH FLOOR OAKLAND CA 946123433 941105628 501(C)(3) 18005 BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI KAISER FOUNDATION HOSPITALS 1800 HARRISON ST 16TH FLOOR OAKLAND CA 946123433 941105628 501(C)(3) 354824 CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE KAISER FOUNDATION HOSPITALS 1800 HARRISON ST 16TH FLOOR OAKLAND CA 946123433 941105628 501(C)(3) 637986 MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS KAISER FOUNDATION HOSPITALS 1800 HARRISON ST 16TH FLOOR OAKLAND CA 946123433 941105628 501(C)(3) 7873 PARTNERSHIP FOR THE ADVANCEMENT OF CANCER RESEARCH: NMS KAISER FOUNDATION HOSPITALS 1800 HARRISON ST 16TH FLOOR OAKLAND CA 946123433 941105628 501(C)(3) 49911 UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES LABKEY CORPORATION 2226 EASTLAKE AVE E 101 SEATTLE WA 98102 208266728 501(C)(3) 165824 CROSS-SPECIES HIV IMMUNOLOGY STATISTICS AND DATA CENTER LABKEY CORPORATION 2226 EASTLAKE AVE E 101 SEATTLE WA 98102 208266728 501(C)(3) 368213 HVTN SDMC: LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORK LOUISIANA STATE UNIVERSITY HEALTH 433 BOLIVAR ST NEW ORLEANS LA 701122223 726087770 UNIVERSITY 44528 IMMUNIZATION OF ORAL MUCOSA FOR INDUCTION OF RECTAL AND MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 042103594 501(C)(3) 222708 HVTN LABORATORY PROGRAM MAYO CLINIC ROCHESTER P O BOX 4008 ROCHESTER MN 559034008 416011702 501(C)(3) 64014 BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI MEDICAL COLLEGE OF WISCONSIN INC 8701 WATERTOWN PLANK RD MILWAUKEE WI 532260509 390806261 501(C)(3) 33058 HEMATOPOIETIC STEM CELL AND CORD BLOOD TRANSPLANTATION MEDICAL COLLEGE OF WISCONSIN INC 8701 WATERTOWN PLANK RD MILWAUKEE WI 532260509 390806261 501(C)(3) 4204 HEMATOPOPIETIC STEM CELL TRANSPLANTATION MEDICAL COLLEGE OF WISCONSIN INC 8701 WATERTOWN PLANK RD MILWAUKEE WI 532260509 390806261 501(C)(3) 21661 IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GVHD MEDICAL UNIVERSITY OF SOUTH CAROLINA 19 HAGOOD AVE SUITE 303 MSC 804 CHARLESTON SC 294258040 576000722 UNIVERSITY 12400 HVTN LABORATORY PROGRAM MEDICAL UNIVERSITY OF SOUTH CAROLINA 19 HAGOOD AVE SUITE 303 MSC 804 CHARLESTON SC 294258040 576000722 UNIVERSITY 11549 RADIATION DOSE-DEPENDENT INTERVENTIONS MIRIAM HOSPITAL 593 EDDY ST PROVIDENCE RI 02903 050258905 501(C)(3) 182914 HVTN LABORATORY PROGRAM MIRIAM HOSPITAL 593 EDDY ST PROVIDENCE RI 02903 050258905 501(C)(3) 14823 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL MOUNT SINAI SCHOOL OF MEDICINE ONE GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501(C)(3) 18336 A POOLED ANALYSIS OF RISK FACTORS OF SMALL INTESTINE NATIONAL INSTITUTES OF HEALTH 10 CENTER DR CRC RM 3-330 BETHESDA MD 20892 520858115 NATIONAL INSTITUTES 190000 HARNESSING INNATE IMMUNITY TO ENHANCE IMMUNOGENICITY NATIONAL MARROW DONOR PROGRAM P O BOX 1450 MINNEAPOLIS MN 554858428 840865803 501(C)(3) 93607 HEMATOPOIETIC STEM CELL AND CORD BLOOD TRANSPLANTATION NEW YORK BLOOD CENTER INC 1200 PROSPECT AVENUE WESTBURY NY 11590 131949477 501(C)(3) 1147062 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL NEW YORK UNIVERSITY SCHOOL OF MEDICINE 545 FIRST AVENUE NEW YORK NY 10016 135562309 UNIVERSITY 80924 HARNESSING INNATE IMMUNITY TO ENHANCE IMMUNOGENICITY NEW YORK UNIVERSITY SCHOOL OF MEDICINE 545 FIRST AVENUE NEW YORK NY 10016 135562309 UNIVERSITY 32543 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL NORTHEASTERN UNIVERSITY 360 HUNTINGTON AVE BOSTON MA 02115 041679980 501(C)(3) 170989 NOVEL CULTIVATION METHODS FOR THE DOMESTICATION OF VAGIN NORTHWEST COMMUNITIES EDUCATION CENTER P O BOX 800 GRANGER WA 98932 910969818 501(C)(3) 26160 PARTNERSHIP FOR A HISPANIC DIABETES PREVENTION PROGRAM NORTHWEST PORTLAND AREA INDIAN 2121 SW BROADWAY STE 300 PORTLAND OR 97201 930718154 501(C)(3) 26938 A MULTI-STATE STUDY OF CANCER TREATMENT AND OUTCOME NY CITY DEPT OF HLTH AND MENTAL HYGIENE 42-09 28TH ST CN 48 QUEENS NY 111014132 136400434 501(C)(3) 488989 HPTN SDMC: LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORK OHIO STATE UNIVERSITY RSRCH FOUNDATION 1960 KENNY RD COLUMBUS OH 432101063 316401599 501(C)(3) 19412 A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE L OHIO STATE UNIVERSITY RSRCH FOUNDATION 1960 KENNY RD COLUMBUS OH 432101063 316401599 501(C)(3) 41865 EPIDEMIOLOGY OF PUTATIVE GENETIC GENETIC VARIANTS OHIO STATE UNIVERSITY RSRCH FOUNDATION 1960 KENNY RD COLUMBUS OH 432101063 316401599 501(C)(3) 13343 GWAS OF HORMONE TREATMENT AND CVD AND METABOLIC OUTCOMES OREGON HEALTH & SCIENCE UNIVERSITY 0690 SW BANCROFT ST PORTLAND OR 97239 931176109 UNIVERSITY 476211 HARNESSING INNATE IMMUNITY TO ENHANCE IMMUNOGENICITY OREGON HEALTH & SCIENCE UNIVERSITY 0690 SW BANCROFT ST PORTLAND OR 97239 931176109 UNIVERSITY 1110213 IMMUNE CORRELATES OF PROTECTION AGAINST HIV AND SIV INFE OREGON HEALTH & SCIENCE UNIVERSITY 0690 SW BANCROFT ST PORTLAND OR 97239 931176109 UNIVERSITY 634967 IMMUNIZATION OF ORAL MUCOSA FOR INDUCTION OF RECTAL AND OREGON HEALTH & SCIENCE UNIVERSITY 0690 SW BANCROFT ST PORTLAND OR 97239 931176109 UNIVERSITY 93900 THE PACIFIC NORTHWEST PROSTATE CANCER SPORE OREGON UNIVERSITY SYSTEM 5219 UNIVERSITY OF OREGON EUGENE OR 974035219 936001786 UNIVERSITY 89712 TILLING THE ZEBRAFISH GENOME: A REVERSE GENETICS APPROACH PRESIDENT AND FELLOWS OF HARVARD COLLEGE P O BOX 415649 BOSTON MA 022415649 042103580 501(C)(3) 180034 EPIGENOMIC PROFILING OF HISTONE TURNOVER KINETICS PRESIDENT AND FELLOWS OF HARVARD COLLEGE P O BOX 415649 BOSTON MA 022415649 042103580 501(C)(3) 114214 GENOME-WIDE PROFILING OF HISTONE VARIANTS IN DROSOPHILA PRESIDENT AND FELLOWS OF HARVARD COLLEGE P O BOX 415649 BOSTON MA 022415649 042103580 501(C)(3) 42421 GENOME-WIDE PROFILINGOF HISTONE VARIANTS IN DROSOPHILA PRESIDENT AND FELLOWS OF HARVARD COLLEGE P O BOX 415649 BOSTON MA 022415649 042103580 501(C)(3) 24502 HVTN LABORATORY PROGRAM PRESIDENT AND FELLOWS OF HARVARD COLLEGE P O BOX 415649 BOSTON MA 022415649 042103580 501(C)(3) 36535 STATISTICAL METHODS FOR PROSPECTIVE EVALUATION PROVIDENCE HEALTH & SERVICES-OREGON 4805 NE GLISAN ST SUITE 5F40 PORTLAND OR 97213 930386906 HOSPITAL 8880 A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE L PUBLIC HEALTH FOUNDATION ENTERPRISES INC 12801 CROSSROADS PARKWAY SOUTH 200 CITY OF INDUSTRY CA 91746 952557063 501(C)(3) 1087008 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL PUGET SOUND BLOOD CENTER AND PROGRAM 921 TERRY AVENUE SEATTLE WA 981041256 911019655 501(C)(3) 11240 CORE CENTER OF EXCELLENCE IN HEMATOLOGY PUGET SOUND BLOOD CENTER AND PROGRAM 921 TERRY AVENUE SEATTLE WA 981041256 911019655 501(C)(3) 11414 THERAPIES FOR HEMATOPOIETIC SYNDROME, BONE MARROW STROMA REGENTS OF THE UNIV OF CALIFORNIA ACCOUNTING OFFICE - EMF BOX 0897 SAN FRANCISCO CA 94143 946036493 UNIVERSITY 81534 BARRETT'S ESOPHAGUS: PREDICTORS OF PROGRESSION REGENTS OF THE UNIV OF CALIFORNIA ACCOUNTING OFFICE - EMF BOX 0897 SAN FRANCISCO CA 94143 946036493 UNIVERSITY 129121 MECHANISM-BASED CLASSIFICATION AND TARGETING OF CASTRATI REGENTS OF THE UNIV OF CALIFORNIA ACCOUNTING OFFICE - EMF BOX 0897 SAN FRANCISCO CA 94143 946036493 UNIVERSITY 36781 MODELING PROSTATE CANCER CONTROL: PREVENTION AND SCREENING REGENTS OF THE UNIVERSITY OF CALIFORNIA IRVINE BIOLOGICAL SCIENCES III SUITE 1400 IRVINE CA 926971050 952226406 UNIVERSITY 44800 EARLY AND REINFECTION IN HIGH RISK WOMEN REGENTS OF THE UNIVERSITY OF CALIFORNIA CASHIERS OFFICE P O BOX 989062 WEST SACRAMENTO CA 957989062 946036494 UNIVERSITY 65865 A PROSPECTIVE STUDY OF COLORECTAL CANCER REGENTS OF THE UNIVERSITY OF CALIFORNIA CASHIERS OFFICE P O BOX 989062 WEST SACRAMENTO CA 957989062 946036494 UNIVERSITY 25909 BIOMARKER DISCOVERY FOR MITOCHONDRIAL TOXICANTS REGENTS OF THE UNIVERSITY OF CALIFORNIA CASHIERS OFFICE P O BOX 989062 WEST SACRAMENTO CA 957989062 946036494 UNIVERSITY 190452 BISPECIFIC ANTIBODY ENGINEERING FOR AML RIT REGENTS OF THE UNIVERSITY OF CALIFORNIA CASHIERS OFFICE P O BOX 989062 WEST SACRAMENTO CA 957989062 946036494 UNIVERSITY 19446 STATISTICAL METHODS FOR INTEGRATIVE ANALYSIS OF GENOMICS REGENTS OF THE UNIVERSITY OF MICHIGAN 24 FRANK LLOYD WRIGHT DRIVE ANN ARBOR MI 48106 386006309 UNIVERSITY 22955 A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE L REGENTS OF THE UNIVERSITY OF MICHIGAN 24 FRANK LLOYD WRIGHT DRIVE ANN ARBOR MI 48106 386006309 UNIVERSITY 51660 CENTER FOR COMPARATIVE EFFECTIVENESS RESEARCH IN CANCER REGENTS OF THE UNIVERSITY OF MICHIGAN 24 FRANK LLOYD WRIGHT DRIVE ANN ARBOR MI 48106 386006309 UNIVERSITY 243788 MODELING PROSTATE CANCER CONTROL: PREVENTION AND SCREENING REGENTS OF THE UNIVERSITY OF MINNESOTA NW 5957 P O BOX 1450 MINNEAPOLIS MN 554855957 416007513 UNIVERSITY 748480 CORE ASSAYS MRLI - W1, W3 REGENTS OF THE UNIVERSITY OF MINNESOTA NW 5957 P O BOX 1450 MINNEAPOLIS MN 554855957 416007513 UNIVERSITY 7554 CTRIP: NOTCH-MEDIATED EXPANSION OF CORD BLOOD PROGENITOR REGENTS OF THE UNIVERSITY OF MINNESOTA NW 5957 P O BOX 1450 MINNEAPOLIS MN 554855957 416007513 UNIVERSITY 65411 IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC REGENTS OF THE UNIVERSITY OF MINNESOTA NW 5957 P O BOX 1450 MINNEAPOLIS MN 554855957 416007513 UNIVERSITY 78656 IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GVHD REGENTS OF THE UNIVERSITY OF MINNESOTA NW 5957 P O BOX 1450 MINNEAPOLIS MN 554855957 416007513 UNIVERSITY 99607 INTERGRATED SENSOR TECHNOLOGY FOR REAL-TIME RECORDING OF REGENTS OF THE UNIVERSITY OF MINNESOTA NW 5957 P O BOX 1450 MINNEAPOLIS MN 554855957 416007513 UNIVERSITY 80182 MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS REGENTS OF THE UNIVERSITY OF MINNESOTA NW 5957 P O BOX 1450 MINNEAPOLIS MN 554855957 416007513 UNIVERSITY 13422 METABOLIC SYNDROME FOLLOWING TRANSPLANT FOR LEUKEMIA REGENTS OF UNIVERSITY OF COLORADO P O BOX 910238 DENVER CO 802910238 846000555 UNIVERSITY 26684 CTRIP: NOTCH-MEDIATED EXPANSION OF CORD BLOOD PROGENITOR REGENTS OF UNIVERSITY OF COLORADO P O BOX 910238 DENVER CO 802910238 846000555 UNIVERSITY 1046667 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL REGENTS OF UNIVERSITY OF COLORADO P O BOX 910238 DENVER CO 802910238 846000555 UNIVERSITY 26225 VITAMIN D AND PROSTATE CANCER: BIOMARKERS AND GENETIC VA REGENTS UNIVERSITY OF CALIF AT LOS ANGELES 405 HILGARD AVENUE LOS ANGELES CA 900959000 956006143 UNIVERSITY 51116 EVALUATION OF A HEPATITIS B OUTREACH INTERVENTION FOR CA REGENTS UNIVERSITY OF CALIF AT LOS ANGELES 405 HILGARD AVENUE LOS ANGELES CA 900959000 956006143 UNIVERSITY 25990 GWAS OF HORMONE TREATMENT AND CVD AND METABOLIC OUTCOMES REGENTS UNIVERSITY OF CALIF AT LOS ANGELES 405 HILGARD AVENUE LOS ANGELES CA 900959000 956006143 UNIVERSITY 201670 HVTN LABORATORY PROGRAM REGENTS UNIVERSITY OF CALIF AT LOS ANGELES 405 HILGARD AVENUE LOS ANGELES CA 900959000 956006143 UNIVERSITY 52112 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL REGENTS UNIVERSITY OF CALIF AT LOS ANGELES 405 HILGARD AVENUE LOS ANGELES CA 900959000 956006143 UNIVERSITY 72524 MARKERS OF B-CELL STIMULATION AS POTENTIAL PREDICTORS OF RESEARCH FOUNDATION OF STATE UNIVERSITY P O BOX 9 ALBANY NY 122010009 141368361 501(C)(3) 26172 OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN RESEARCH FOUNDATION OF STATE UNIVERSITY P O BOX 9 ALBANY NY 122010009 141368361 501(C)(3) 82221 POPULATION PHARMACOKINETICS / PHARMACODYNAMICS IN NONABL RHODE ISLAND HOSPITAL 593 EDDY ST PROVIDENCE RI 02903 050258954 501(C)(3) 32325 HVTN LABORATORY PROGRAM SAINT JUDE CHILDRENS RESEARCH HOSPITAL 262 DANNY THOMAS PL MEMPHIS TN 381480949 620646012 501(C)(3) 13511 LATE EFFECTS OF TREATMENT IN WILMS-TUMOR SURVIVORS AND O SAINT LOUIS UNIVERSITY 3700 WEST PINE MALL SAINT LOUIS MO 63108 430654872 501(C)(3) 14976 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL SANGAMO BIOSCIENCES INC 501 CANAL BLVD SUITE A100 RICHMOND CA 94804 680359556 441408 TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT SEA MAR COMMUNITY HEALTH CENTER 8915 14TH AVE S SEATTLE WA 98108 911020139 121251 UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES SEATTLE BIOMEDICAL RESEARCH INSTITUTE 307 WESTLAKE AVE N SUITE 500 SEATTLE WA 981095219 910961784 501(C)(3) 350165 HARNESSING INNATE IMMUNITY TO ENHANCE IMMUNOGENICITY OF SEATTLE BIOMEDICAL RESEARCH INSTITUTE 307 WESTLAKE AVE N SUITE 500 SEATTLE WA 981095219 910961784 501(C)(3) 43601 N/A SEATTLE BIOMEDICAL RESEARCH INSTITUTE 307 WESTLAKE AVE N SUITE 500 SEATTLE WA 981095219 910961784 501(C)(3) 21176 WASHINGTON VACCINE ALLIANCE SEATTLE CHILDREN'S HOSPITAL P O BOX 24728 SEATTLE WA 981240728 910564748 501(C)(3) 4702 A COMPREHENSIVE CATALOGUE OF MOUSE DNASEI HYPERSENSITIVE SEATTLE CHILDREN'S HOSPITAL P O BOX 24728 SEATTLE WA 981240728 910564748 501(C)(3) 101896 CANCER CENTER SUPPORT GRANT (COMPREHENSIVE) SEATTLE CHILDREN'S HOSPITAL P O BOX 24728 SEATTLE WA 981240728 910564748 501(C)(3) 231451 CONSORTIUM BIOSPECIMEN PROGRAM SEATTLE CHILDREN'S HOSPITAL P O BOX 24728 SEATTLE WA 981240728 910564748 501(C)(3) 10865 DIETARY FRUCTOSE AND LOW-GRADE INFLAMMATION SEATTLE CHILDREN'S HOSPITAL P O BOX 24728 SEATTLE WA 981240728 910564748 501(C)(3) 36145 METABOLIC SYNDROME FOLLOWING TRANSPLANT FOR LEUKEMIA SEATTLE CHILDREN'S HOSPITAL P O BOX 24728 SEATTLE WA 981240728 910564748 501(C)(3) 25064 PREGNANCY, MICROCHIMERISM, AND AUTOIMMUNE DISEASE SEATTLE CHILDREN'S HOSPITAL P O BOX 24728 SEATTLE WA 981240728 910564748 501(C)(3) 49570 STEM CELL TRANSPLANTATION: BASIC/CLINICAL RESEARCH SEATTLE CHILDREN'S HOSPITAL P O BOX 24728 SEATTLE WA 981240728 910564748 501(C)(3) 110227 TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT SEATTLE CHILDREN'S HOSPITAL P O BOX 24728 SEATTLE WA 981240728 910564748 501(C)(3) 271421 TARGETED THERAPY OF ALL WITH GENE-MODIFIED CENTRAL MEMOR SEATTLE CHILDREN'S HOSPITAL P O BOX 24728 SEATTLE WA 981240728 910564748 501(C)(3) 11637 TOWARDS A MODEL OF FANCONI ANEMIA SEATTLE CHILDREN'S HOSPITAL P O BOX 24728 SEATTLE WA 981240728 910564748 501(C)(3) 12021 WHOLE GENOME ASSOCIATION ANALYSIS OF HEMATOPOIETIC CELL SEATTLE INST FOR BIOMED & CLINICAL RES 1100 OLIVE WAY SUITE 940 SEATTLE WA 98101 911452438 501(C)(3) 45251 IN VIVO EFFECTS OF SULFORAPHANE SUPPLEMENTATION ON NORMA SEATTLE INST FOR BIOMED & CLINICAL RES 1100 OLIVE WAY SUITE 940 SEATTLE WA 98101 911452438 501(C)(3) 120214 THE PACIFIC NORTHWEST PROSTATE CANCER SPORE SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH P O BOX 26338 NEW YORK NY 10087 131624182 501(C)(3) 50688 GENOME-WIDE ASSOCIATION STUDY OF ENDOMETRIAL CANCER SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH P O BOX 26338 NEW YORK NY 10087 131624182 501(C)(3) 207092 HEMATOPOIETIC STEM CELL AND CORD BLOOD TRANSPLANTATION SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH P O BOX 26338 NEW YORK NY 10087 131624182 501(C)(3) 39736 HEMATOPOPIETIC STEM CELL TRANSPLANTATION STATE OF FLORIDA DEPT OF HEALTH 4052 BALD CYPRESS WAY BIN B20 TALLAHASSEE FL 323991729 593502843 17690 HPTN SDMC: LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORK SUNNYSIDE COMMUNITY HOSPITAL INC P O BOX 719 SUNNYSIDE WA 98944 911286274 501(C)(3) 49500 PARTNERSHIP FOR A HISPANIC DIABETES PREVENTION PROGRAM SWEDISH HEALTH SERVICES P O BOX 94085 SEATTLE WA 981249485 910433740 501(C)(3) 38758 BREAST AND OVARY CANCER CLINICAL VALIDATION CENTER SWEDISH HEALTH SERVICES P O BOX 94085 SEATTLE WA 981249485 910433740 501(C)(3) 11000 PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM SWEDISH HEALTH SERVICES P O BOX 94085 SEATTLE WA 981249485 910433740 501(C)(3) 2570 PREVENTION OF OVARIAN CANCER IN WOMEN PARTICIPATING TORREY PINES INST FOR MOLECULAR STUDIES 11350 SW VILLAGE PARKWAY PORT ST LUCIE FL 34987 330319501 501(C)(3) 33533 IDENTIFICATION OF T CELL-DEFINED ANTIGENS IN OVARIAN CAN TRANSLATIONAL GENOMICS RES INSTITUTE 445 N 5TH ST SUITE 600 PHOENIX AZ 85004 753065445 501(C)(3) 87882 A PROSPECTIVE STUDY OF COLORECTAL CANCER TRANSLATIONAL GENOMICS RES INSTITUTE 445 N 5TH ST SUITE 600 PHOENIX AZ 85004 753065445 501(C)(3) 2457953 COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES TRANSLATIONAL GENOMICS RES INSTITUTE 445 N 5TH ST SUITE 600 PHOENIX AZ 85004 753065445 501(C)(3) 1147764 EPIDEMIOLOGY OF PUTATIVE GENETIC GENETIC VARIANTS TRANSLATIONAL GENOMICS RES INSTITUTE 445 N 5TH ST SUITE 600 PHOENIX AZ 85004 753065445 501(C)(3) 348262 EPIDEMIOLOGY OF PUTATIVE GENUINE GENETIC VARIANT TRANSLATIONAL GENOMICS RES INSTITUTE 445 N 5TH ST SUITE 600 PHOENIX AZ 85004 753065445 501(C)(3) 135035 GENOME-WIDE ASSOCIATION STUDY OF NONSYNONYMOUS SNPS TRANSLATIONAL GENOMICS RES INSTITUTE 445 N 5TH ST SUITE 600 PHOENIX AZ 85004 753065445 501(C)(3) 225000 INFLAMMATION AND THROMBOSIS GENE PATHWAYS AND CARDIOVASC TRUSTEES OF COLUMBIA UNIVERSITY IN NY P O BOX 29789 NEW YORK NY 100879789 135598093 501(C)(3) 1436339 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRUSTEES OF THE UNIV OF PENNSYLVANIA 3451 WALNUT ST PHILADELPHIA PA 191046205 231352685 501(C)(3) 2770 A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE L TRUSTEES OF THE UNIV OF PENNSYLVANIA 3451 WALNUT ST PHILADELPHIA PA 191785541 231352685 501(C)(3) 6182 GENOME-WIDE ASSOCIATION STUDY OF ENDOMETRIAL CANCER TRUSTEES OF THE UNIV OF PENNSYLVANIA 3451 WALNUT ST PHILADELPHIA PA 191785541 231352685 501(C)(3) 1204938 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRUSTEES OF THE UNIV OF PENNSYLVANIA 3451 WALNUT ST PHILADELPHIA PA 191046205 231352685 501(C)(3) 169780 MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS UNIVERSITY OF ALABAMA BIRMINGHAM 1530 THIRD AVENUE SOUTH BIRMINGHAM AL 352940109 636005396 UNIVERSITY 932250 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL UNIVERSITY OF FLORIDA P O BOX 113001 GAINESVILLE FL 326113001 596002052 UNIVERSITY 90229 METHODS FOR EVALUATING VACCINE EFFICACY UNIVERSITY OF GEORGIA RESEARCH 475 N LUMPKIN ST ATHENS GA 30602 581353149 501(C)(3) 182315 A PROSPECTIVE STUDY OF COLORECTAL CANCER: ONE-CARBON ME UNIVERSITY OF GEORGIA RESEARCH 475 N LUMPKIN ST ATHENS GA 30602 581353149 501(C)(3) 26819 FUNCTIONAL METHODS FOR RADIATION EXPOSURE AND BIOMARKER UNIVERSITY OF HAWAII 2530 DOLE ST HONOLULU HI 96822 996000354 UNIVERSITY 100354 COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSOR UNIVERSITY OF IDAHO P O BOX 443020 MOSCOW ID 838443020 826000945 UNIVERSITY 70933 WASHINGTON VACCINE ALLIANCE UNIVERSITY OF NEW MEXICO 1 UNIVERSITY OF NEW MEXICO ALBUQUERQUE NM 871310001 856000642 UNIVERSITY 4849 REDUCING OBESITY AT THE WORKPLACE: A RANDOMIZED TRIAL UNIVERSITY OF NEW MEXICO 1 UNIVERSITY OF NEW MEXICO ALBUQUERQUE NM 871310001 856000642 UNIVERSITY 26686 TREC COORDINATION CENTER UNIVERSITY OF NEW MEXICO 1 UNIVERSITY OF NEW MEXICO ALBUQUERQUE NM 871310001 856000642 UNIVERSITY 295 TREC: MECHANISMS OF ENERGY BALANCE AND CANCER PREVENTION UNIVERSITY OF NEW MEXICO 1 UNIVERSITY OF NEW MEXICO ALBUQUERQUE NM 871310001 856000642 UNIVERSITY 298854 UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE 9201 UNIVERSITY CITY BOULEVARD CHARLOTTE NC 282230001 560791228 UNIVERSITY 80319 STATISTICAL METHODS IN HIV VACCINE EFFICACY TRIALS UNIVERSITY OF NORTH CAROLINA P O BOX 402420 ATLANTA GA 303842420 566001393 UNIVERSITY 165208 BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI UNIVERSITY OF NORTH CAROLINA P O BOX 402420 ATLANTA GA 303842420 566001393 UNIVERSITY 248140 CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INIT UNIVERSITY OF NORTH CAROLINA P O BOX 402420 ATLANTA GA 303842420 566001393 UNIVERSITY 7058 MEASUREMENT OF CANCER-ASSOCIATED BIOMARKER PROTEINS IN C UNIVERSITY OF NORTH CAROLINA P O BOX 402420 ATLANTA GA 303842420 566001393 UNIVERSITY 84666 MECHANISM-BASED CLASSIFICATION AND TARGETING OF CASTRATI UNIVERSITY OF NORTH CAROLINA P O BOX 402420 ATLANTA GA 303842420 566001393 UNIVERSITY 45014 OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN UNIVERSITY OF NORTH CAROLINA P O BOX 402420 ATLANTA GA 303842420 566001393 UNIVERSITY 37249 STATISTICAL METHODS IN HIV VACCINE EFFICACY TRIALS UNIVERSITY OF PITTSBURGH P O BOX 371220 PITTSBURGH PA 152517220 250965591 501(C)(3) 5495 A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE L UNIVERSITY OF PITTSBURGH P O BOX 371220 PITTSBURGH PA 152517220 250965591 501(C)(3) 20373 COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSOR UNIVERSITY OF PITTSBURGH P O BOX 371220 PITTSBURGH PA 152517220 250965591 501(C)(3) 11967 EPIDEMIOLOGY OF PUTATIVE GENETIC GENETIC VARIANTS IN THE UNIVERSITY OF PITTSBURGH P O BOX 371220 PITTSBURGH PA 152517220 250965591 501(C)(3) 21893 GWAS OF HORMONE TREATMENT AND CVD AND METABOLIC OUTCOMES UNIVERSITY OF PITTSBURGH P O BOX 371220 PITTSBURGH PA 152517220 250965591 501(C)(3) 27297 HVTN LABORATORY PROGRAM UNIVERSITY OF ROCHESTER 910 GENESEE ST SUITE 200 ROCHESTER NY 146113847 160743209 501(C)(3) 1326849 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL UNIVERSITY OF ROCHESTER 910 GENESEE ST SUITE 200 ROCHESTER NY 146113847 160743209 501(C)(3) 141355 THE PATHOGENESIS OF FMD: FACIOSCAPULOHUMERAL MUSCULAR UNIVERSITY OF SOUTHERN CALIFORNIA 3500S FIGUEROA ST SUITE 102 LOS ANGELES CA 900742095 951642394 501(C)(3) 101314 BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI UNIVERSITY OF SOUTHERN CALIFORNIA 3500S FIGUEROA ST SUITE 102 LOS ANGELES CA 900898001 951642394 501(C)(3) 8426 BREAST CANCER BIOMARKER DISCOVERY CONSORTIUM - SUPPLEMEN UNIVERSITY OF SOUTHERN CALIFORNIA 3500S FIGUEROA ST SUITE 102 LOS ANGELES CA 900742095 951642394 501(C)(3) 83916 COG CHAIR'S GRANT - PROJECT TARGET IDENTIFICATION FOR HI UNIVERSITY OF SOUTHERN CALIFORNIA 3500S FIGUEROA ST SUITE 102 LOS ANGELES CA 900742095 951642394 501(C)(3) 120605 IMPROVING EARLY DETECTION OF BREAST CANCER UNIVERSITY OF SOUTHERN CALIFORNIA 3500S FIGUEROA ST SUITE 102 LOS ANGELES CA 900742095 951642394 501(C)(3) 6287 IRF8 AS A BIOMARKER OF AGING, MALIGNANT TRANSFORMATION, UNIVERSITY OF SOUTHERN CALIFORNIA 3500S FIGUEROA ST SUITE 102 LOS ANGELES CA 900898015 951642394 501(C)(3) 24648 THE BREAST CANCER BIOMARKER DISCOVERY CONSORTIUM: PHASE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL P O BOX 841765 DALLAS TX 752841765 756002868 UNIVERSITY 807800 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL UNIVERSITY OF TEXAS MD ANDERSON P O BOX 4390 HOUSTON TX 772104390 746001118 36960 IMPROVING EARLY DETECTION OF BREAST CANCER WITH A BLOOD UNIVERSITY OF TEXAS MD ANDERSON P O BOX 4390 HOUSTON TX 772104390 746001118 19483 THE BREAST CANCER BIOMARKER DISCOVERY CONSORTIUM: PHASE UNIVERSITY OF UTAH 201 S PRESIDENTS CIRCLE RM 406 SALT LAKE CITY UT 841129020 876000525 UNIVERSITY 85837 GENOME-WIDE ASSOCIATION STUDY OF NONSYNONYMOUS SNPS IN C UNIVERSITY OF UTAH 201 S PRESIDENTS CIRCLE RM 406 SALT LAKE CITY UT 841129020 876000525 UNIVERSITY 28420 PROSTAGLANDIN SYNTHESIS, GENETICS AND COLORECTAL CANCER UNIVERSITY OF UTAH 201 S PRESIDENTS CIRCLE RM 406 SALT LAKE CITY UT 841129020 876000525 UNIVERSITY 32483 THE TIME DISTRIBUTION METHOD FOR MEASURING CLINICALLY VA UNIVERSITY OF VERMONT AND 85 SOUTH PROSPECT ST BURLINGTON VT 054050160 030179440 UNIVERSITY 12003 A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE L UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 14577 A MULTI-STATE STUDY OF CANCER TREATMENT AND OUTCOME AMON UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 27655 A PROSPECTIVE STUDY OF COLORECTAL CANCER: ONE-CARBON ME UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 57410 A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE L UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 13173 ADIPOSE TISSUE INFLAMMATION AND ESTROGEN SYNTHESIS UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 12862 AFFINITY BASED STRATEGIES TO FAST TRACK DEVELOPMENT OF C UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 12989 AIDS MALIGNANCY CLINICAL TRIALS (AMC) UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 27112 AIDS MALIGNANCY CLINICAL TRIALS CONSORTIUM (AMC) UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 1059 AN ALGORITHM FOR CONTROL OF BIOLOGICAL TIME UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 5582 ANALYSIS OF A NOVEL SUBSET OF HUMAN CD8+ MEMORY CELLS WI UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 54703 ANALYZING HETEROGENEITY OF ONCOGENIC PATHWAY ACTIVATION UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 23037 ASTATINE-211 CONDITIONING FOR NONMYELOABLATIVE HEMOPOIET UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 43361 BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 1924553 CANCER CENTER SUPPORT GRANT (COMPREHENSIVE) UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 457568 CANCER IMMUNOTHERAPY TRIALS NETWORK CENTRAL OPERATIONS UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 39342 CD38 PRETARGETED RADIOIMMUNOTHERAPY FOR MYELOMA UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 68367 CD45 PRETARGETED RADIOIMMUNOTHERAPY FOR AML UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 133111 CD8+ CELL IMMUNITY TO CYTOMEGALOVIRUS UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 313388 CENTER FOR BIOLOGICAL FUTURES UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 137821 CENTER FOR COMPARATIVE EFFECTIVENESS RESEARCH IN CANCER UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 172248 CHARACTERIZATION OF HIV-1 ANTIBODY RESPONSES IN CHRONICA UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 95818 CHEMOPROTECTION AGAINST AMINOGLYCOSIDE-INDUCED OTOTOXICI UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 3615 CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INIT UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 1623449 CLINICAL EPIDEMIOLOGY AND PATHOGENESIS OF ASYMPTOMATIC H UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 92600 COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSOR UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 748752 CONSORTIUM BIOSPECIMEN PROGRAM UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 132966 CONTROLLING HEMATOPOIETIC LINEAGE COMMITMENT FROM ESC TO UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 89571 CORD BLOOD EXPANSION AND TRANSPLANTATION IN A NON-HUMAN UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 3119 CORE ASSAYS MRLI - W1, W3 UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 6345 CORE CENTER OF EXCELLENCE IN HEMATOLOGY UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 137620 CYTOTOXIC T CELL RESPONSE TO HSV IN HIV INFECTED PEOPLE UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 27998 CYTOTOXIC T-CELL REPONSES TO HSV IN HIV-INFECTED PERSONS UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 175698 DEVELOPMENT OF NOVEL AIDS GENE THERAPY STRATEGIES IN THE UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 275024 DEVELOPMENT OF SAFE AND EFFICIENT GENE THERAPY STRATEGIE UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 3452 DIETARY FRUCTOSE AND LOW-GRADE INFLAMMATION UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 290524 EARLY AND REINFECTION IN HIGH RISK WOMEN UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 28438 ENHANCING LONG-TERM 5-A-DAY BEHAVIOR CHANGE IN WORKSITES UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 32990 EVALUATION OF A HEPATITIS B OUTREACH INTERVENTION FOR CA UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 8250 EXOSOMAL RNAS SERUM PROSTATE CANCER BIOMARKERS UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 216744 EXPANSION OF CARDIAC AND HEMATOPOIETIC PREGENITORS BY WN UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 73813 FHCRC/UW CANCER CONSORTIUM PHASE I CLINICAL TRIALS PROGR UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 4165 FOAMY VIRUS ZOONOTIC TRANSMISSION FROM NEW WORLD MONKEYS UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 111497 FRED HUTCHINSON/UNIVERSITY OF WASHINGTON CANCER CONSORTI UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 5722 GENE THERAPY FOR FANCONI ANEMIA UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 4825 HEMATOPOIETIC CHEMOPROTECTION IN GLIOBLASTOMA PATIENTS UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 220067 HPTN SDMC: LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWO UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 25733 HPV CAPSID ANTIBODIES UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 8864 HPV: BIOLOGY, CLINICAL SIGNIFICANCE AND EPIDEMIOLOGY UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 2952256 HVTN LABORATORY PROGRAM UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 66520 HVTN SDMC: LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWO UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 3809825 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 6631 IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 266 IMMUNE CORRELATES OF PROTECTION AGAINST HIV AND SIV INFE UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 82734 IMMUNOTHERAPY OF HEMATOLOGICAL MALIGNANCIES UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 53177 IN UTERO TRANSPLANTATION IN PRIMATES UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 34320 IN VIVO EFFECTS OF SULFORAPHANE SUPPLEMENTATION ON NORMA UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 25033 INFLAMMATORY DENDRITIC CELLS IN ADIPOSE TISSUE INFLAMMAT UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 751 INNATE RESISTANCE TO MUCOSAL HSV INFECTION IN HUMANS UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 321559 INTERGRATED SENSOR TECHNOLOGY FOR REAL-TIME RECORDING OF UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 31971 LAGLIDADG DELIVERY AND GENE REPAIR IN CANINE HEMATOPOIET UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 7024 LATE EFFECTS OF TREATMENT IN WILMS TUMOR SURVIVORS AND O UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 80151 LATE EFFECTS OF TREATMENT IN WILMS-TUMOR SURVIVORS AND O UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 75479 LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: MICRO UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 16460 LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 22287 LIVESTRONG SURVIVORSHIP CENTER OF EXCELLENCE UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 816 LYMPH NODE ALTERATIONS IN CANCER UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 1340772 MECHANISMS AND COFACTORS OF HIV TRANSMISSION TO WOMEN UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 53100 MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS F UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 99325 MIXED HEMATOPOIETIC CHIMERISM AFTER STEM CELL ALLOGRAFTS UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 55971 MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 10352 NIGHT SHIFT WORK AND HORMONE LEVELS IN MEN UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 17774 NORTH AMERICAN SHWACHMAN-DIAMOND SYNDROME REGISTRY UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 77876 NOVEL COMPUTATIONAL TOOLS FOR STUDYING THE HUMAN MICROBI UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 205953 NOVEL CULTIVATION METHODS FOR THE DOMESTICATION OF VAGIN UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 15906 NUTRITION AND PHYSICAL ACTIVITY ASSESSMENT STUDY (NPAAS) UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 10940 ORAL CANCER: MOLECULAR PROFILES & CLINICAL OUTCOMES UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 20088 OUTCOMES BASED GUIDELINE DEVELOPMENT FOR PROSTATE CANCER UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 440932 PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 49710 PRECLINICAL GENE THERAPY STUDIES IN CANINE MUSCULAR DYST UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 4312 PRE-DOCTORAL FELLOW - KELLIE VIGNA UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 73202 PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 13689 PROSPR: STATISTICAL COORDINATING CENTER (PSCC) UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 1228 PROTEIN BIOMARKERS IN CHILDHOOD ACUTE MYELOID LEUKEMIA UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 12143 RADIATION DOSE-DEPENDENT INTERVENTIONS UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 16667 REDUCING OBESITY AT THE WORKPLACE: A RANDOMIZED TRIAL UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 337532 SEATTLE CANCER CONSORTIUM BREAST SPORE UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 302981 SEATTLE VACCINE TRIALS UNIT UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 32242 STATISTICAL METHODS FOR MEDICAL STUDIES UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 89248 STATISTICAL METHODS IN HIV/AIDS RESEARCH UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 143667 STRATEGIES TO IMPROVE THE ADOPTIVE TRANSFER OF T CELLS UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 233183 T CELL IMMUNITY TO HSV-2 IN IMMUNE SERONEGATIVE SUBJECTS UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 237900 TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 14750 TARGETED RADIOTHERAPY WITH 90Y-BC8 MONOCLONAL ANTIBODY, UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 1955 TGF-BETA SIGNALING AND COLON CANCER UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 20504 THE FANCONI ANEMIA-BRCA PATHWAY AND CHEMOSENSITIVITY OF UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 555069 THE PACIFIC NORTHWEST PROSTATE CANCER SPORE UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 263959 THE PATHOGENESIS OF FMD: FACIOSCAPULOHUMERAL MUSCULAR UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 77508 THE ROLE OF ANTIBODIES IN MOTHER TO CHILD HIV TRANSMISSI UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 13615 THE ROLE OF UNCULTIVATED BACTERIA IN BACTERIAL VAGINOSIS UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 233286 THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 170107 UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES I UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 181866 WASHINGTON VACCINE ALLIANCE UNIVERSITY OF WASHINGTON NE COLUMBIA RD SEATTLE WA 98105 916001537 UNIVERSITY 63443 WEIGHT LOSS AND EXERCISE EFFECTS ON TELOMERE LENGTH IN P UNIVERSITY OF WISCONSIN DRAWER 538 MILWAUKEE WI 532780538 396006492 UNIVERSITY 2638 CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INIT UNIVERSITY OF WISCONSIN DRAWER 538 MILWAUKEE WI 532780538 396006492 UNIVERSITY 15669 NUTRITION AND PHYSICAL ACTIVITY ASSESSMENT STUDY (NPAAS) VACCINE & GENE THERAPY INSTITUTE FLORIDA 9801 SW DISCOVERY WAY PORT ST LUCIE FL 34987 364631835 501(C)(3) 297409 HVTN LABORATORY PROGRAM VANDERBILT UNIVERSITY DEPT OF FINANCE DEPT AT 40303 ATLANTA GA 311920303 620476822 501(C)(3) 1326637 HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL VANDERBILT UNIVERSITY DEPT OF FINANCE DEPT AT 40303 ATLANTA GA 311920303 620476822 501(C)(3) 17872 IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC VANDERBILT UNIVERSITY DEPT OF FINANCE DEPT AT 40303 ATLANTA GA 311920303 620476822 501(C)(3) 13815 IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GVHD VANDERBILT UNIVERSITY DEPT OF FINANCE DEPT AT 40303 ATLANTA GA 311920303 620476822 501(C)(3) 25180 OUTCOMES BASED GUIDELINE DEVELOPMENT FOR PROSTATE CANCER VANDERBILT UNIVERSITY 2301 VANDERBILT PLACE PMB 401591 NASHVILLE TN 372401591 620476822 501(C)(3) 64074 TILLING THE ZEBRAFISH GENOME: A REVERSE GENETICS APPROAC WAKE FOREST UNIVERSITY HEALTH SCIENCES MEDICAL CENTER BOULEVARD WINSTONSALEM NC 27157 223849199 501(C)(3) 26851 A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE L WAKE FOREST UNIVERSITY HEALTH SCIENCES MEDICAL CENTER BOULEVARD WINSTONSALEM NC 27157 223849199 501(C)(3) 21389 CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INIT WASHINGTON STATE UNIVERSITY P O BOX 641039 PULLMAN WA 991641039 916001108 UNIVERSITY 21434 ENGINEERING ENZYMES FOR ANTI-TUMOR SUICIDE GENE THERAPY WASHINGTON STATE UNIVERSITY P O BOX 641039 PULLMAN WA 991641039 916001108 UNIVERSITY 69119 WASHINGTON VACCINE ALLIANCE WASHINGTON UNIVERSITY 700 ROSEDALE AVE CAMPUS BOX 1034 ST LOUIS MO 631121408 430653611 501(C)(3) 2186 IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC WASHINGTON UNIVERSITY 700 ROSEDALE AVE CAMPUS BOX 1034 ST LOUIS MO 631121408 430653611 501(C)(3) 6632 IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GVHD WASHINGTON UNIVERSITY 700 ROSEDALE AVE CAMPUS BOX 1034 ST LOUIS MO 631121408 430653611 501(C)(3) 4436 RADIATION DOSE-DEPENDENT INTERVENTIONS YAKIMA VALLEY FARM WORKERS CLINIC 518 W FIRST AVENUE TOPPENISH WA 98948 911019392 501(C)(3) 37270 CENTER FOR HISPANIC HEALTH PROMOTION: REDUCING CANCER DI YALE UNIVERSITY P O BOX 1873 NEW HAVEN CT 065081873 060646973 501(C)(3) 104460 ADULT LEUKEMIA RESEARCH CENTER YALE UNIVERSITY P O BOX 1873 NEW HAVEN CT 065081873 060646973 501(C)(3) 22357 BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI YALE UNIVERSITY P O BOX 1873 NEW HAVEN CT 065081873 060646973 501(C)(3) 42591 HIV TESTING AND TREATMENT TO PREVENT ONWARD HIV TRANSMIS YALE UNIVERSITY P O BOX 1873 NEW HAVEN CT 065081873 060646973 501(C)(3) 20664 TREC COORDINATION CENTER 344 13 PROCEDURE FOR MONITORING GRANTS IN THE U.S.: PART I, LINE 2: SCHEDULE I, PART I, LINE 2: ONCE THE NOTICE OF AWARD HAS BEEN RECEIVED AND THE CENTER PROJECT IDENTIFICATION ACTIVATED, THE SUBAWARD CAN BE SET UP. THE STRUCTURE OF THE SUBAWARD WILL DEPEND ON HOW THE PRIME IS SET UP. GENERALLY, AT THE CENTER, A NEW PURCHASE ORDER (PO) IS REQUISITIONED FOR EACH SUBAWARD FOR EACH YEAR OF A PROJECT. THIS ALLOWS THE RESEARCH COORDINATOR (RC) TO CLOSELY MONITOR SUBAWARD INVOICES AND ENCUMBRANCES. FOR OUR SUBRECIPIENTS, IT MEANS A SEPARATE BUDGET IDENTIFICATION AND FINAL INVOICE EACH YEAR. CARRYOVER BETWEEN YEARS IS NOT AUTOMATIC. THERE ARE 5 PRIMARY STEPS IN THIS PROCESS: 1) STEP ONE IS WITHIN THE OFFICE OF SPONSORED RESEARCH (OSR). THE GRANT SPECIALIST NOTIFIES THE CONTRACT SPECIALIST THAT A GRANT WHICH INCLUDES A SUBAWARD HAS BEEN FUNDED, AND PROVIDES TO THE CONTRACT SPECIALIST A COPY OF THE AWARD, THE SIGNED SUBAWARD APPLICATION (IF AVAILABLE) AND ANY SPECIAL INSTRUCTIONS. A SIGNED SUBAWARD APPLICATION IS IMPORTANT BECAUSE IT SHOWS THAT THE SUBRECIPIENT ORGANIZATION HAS REVIEWED AND APPROVED THE BUDGET AND SCOPE OF WORK, 2) THE RC SENDS THE CONTRACT SPECIALIST A SUBCONTRACT ACQUISITION FORM (SAF). THIS FORM PROVIDES AUTHORIZATION FOR THE CONTRACT SPECIALIST TO ISSUE THE SUBAWARD, AND INCLUDES A SCOPE OF WORK, BUDGET, AND PERTINENT SUBRECIPIENT INFORMATION. IT IS NECESSARY TO PROVIDE THE SCOPE OF WORK AND BUDGET ON THE SAF AS THESE ITEMS MAY HAVE CHANGED FROM WHAT WAS ORIGINALLY SUBMITTED IN THE SUBAWARD APPLICATION, 3) THE CONTRACT SPECIALIST REQUISITIONS THE SUBAWARD PO, WHICH THE RC MUST APPROVE. AN E-MAIL IS SENT TO THE RC NOTIFYING THEM THAT THE REQUISITION IS PENDING AND REQUIRES APPROVAL. BECAUSE OSR DOES NOT HAVE FUNDS COMMITMENT AUTHORITY, THE RC IS REQUIRED TO APPROVE ALL REQUISITIONS, 4) OSR COLLECTS INFORMATION REQUIRED TO CORRECTLY SET UP THE SUBAWARD. THESE ITEMS INCLUDE INSTITUTIONAL REVIEW OFFICE (IRO) AND INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) APPROVAL DATES, CONFIRMATION OF SUBAWARD FACILITIES AND ADMINISTRATIVE (F&A) RATES AND A-133 AUDIT REPORTS, REVIEW OF PRIME SPECIAL TERMS AND CONDITIONS TO DETERMINE FLOW-DOWN, CONFIRMATION THAT THE SUBRECIPIENT IS NOT DEBARRED, AND OTHER SIMILAR REGULATORY AND ADMINISTRATIVE REQUIREMENTS. WHILE MUCH OF THE INFORMATION IS COLLECTED BY OSR, THE RC MAY, IN ADDITION TO COMPLETING THE SAF, BE ASKED TO ASSIST IN THE COLLECTION OF SOME OF THE DOCUMENTATION AND FINALLY, 5) OSR WRITES THE SUBAWARD AGREEMENT, AND MAILS IT TO THE SUBRECIPIENT FOR SIGNATURE. SOME AGREEMENTS CAN BE SIGNED BY OSR BEFORE MAILING, WHILE OTHERS WILL BE SENT UNSIGNED. THIS IS DETERMINED BY THE CONTRACT SPECIALIST BASED ON THE TERM OF AWARD AND STATUS OF ADMINISTRATIVE AND REGULATORY REQUIREMENTS. A COPY OF THE INITIAL SUBAWARD IS SENT TO THE RC ONCE THE SUBAWARD HAS BEEN FULLY SIGNED. NO INVOICES SHOULD BE APPROVED BY THE RC UNTIL THEY HAVE RECEIVED A FULLY EXECUTED AGREEMENT. X X X 1 1 X X X X 0 0 0 0 0 0 0 1 0 LAWRENCE COREY MD 606356 0 156250 0 16500 0 0 0 45396 0 824502 0 0 0 FREDERICK R APPELBAUM MD 523908 0 113871 0 0 0 0 0 44646 0 682425 0 0 0 JANELL E BALDWIN 203707 0 20000 0 0 0 0 0 36040 0 259747 0 0 0 ANTHONY J BOZZUTI 233912 0 30000 0 16500 0 0 0 48361 0 328773 0 0 0 JONATHAN A COOPER PHD 282131 0 0 0 0 0 0 0 42684 0 324815 0 0 0 SUSAN C DOLBERT PHD 133580 0 50000 0 0 0 0 0 3060 0 186640 0 0 0 LINDA L GAINER 223902 0 25000 0 0 0 0 0 39739 0 288641 0 0 0 DENISE GALLOWAY PHD 280411 0 0 0 0 0 0 0 43604 0 324015 0 0 0 MARK T GROUDINE MD PHD 412578 0 125000 0 0 0 0 0 45318 0 582896 0 0 0 RANDALL C MAIN 339545 0 50000 0 0 0 0 0 45222 0 434767 0 0 0 MARGARET JULIANA MCELRATH MD PHD 298002 0 0 0 14400 0 0 0 43008 0 355410 0 0 0 ULRICH W MUELLER PHD 234166 0 30000 0 0 0 0 0 48244 0 312410 0 0 0 HOWARD ALBERT NACHTRIEB 218893 0 30000 0 0 0 0 0 48138 0 297031 0 0 0 ROSS L PRENTICE PHD 414412 0 0 0 0 0 0 0 45279 0 459691 0 0 0 SCOTT N RUSCH 186791 0 20000 0 0 0 0 0 39762 0 246553 0 0 0 DOUGLAS J SHAEFFER 305080 0 30000 0 0 0 0 0 45507 0 380587 0 0 0 MYRA H TANITA 408704 0 75000 0 6000 0 0 0 40138 0 529842 0 0 0 STEVEN G SELF PHD 274341 0 0 0 16500 0 0 0 44420 0 335261 0 0 0 SAMIR M HANASH MD 337366 0 0 0 0 0 0 0 43774 0 381140 0 0 0 MARTIN A CHEEVER MD 270695 0 0 0 16500 0 0 0 41796 0 328991 0 0 0 IRWIN D BERNSTEIN MD 291183 0 0 0 16500 0 0 0 42614 0 350297 0 0 0 JANET LEE STANFORD MD 250446 0 0 0 16500 0 0 0 48447 0 315393 0 0 0 BRIAN J REID MD 265064 0 0 0 0 0 0 0 44947 0 310011 0 0 0 PART I, LINE 1A FIRST CLASS AIR TRAVEL IS ALLOWED CONSISTENT WITH FEDERAL REIMBURSEMENT REGULATIONS AND GENERALLY ONLY WHEN COACH FARE IS NOT AVAILABLE. AIRFARE AND NORMAL TRAVEL EXPENSES ARE PAID FOR THE PRESIDENT AND DIRECTOR'S SPOUSE FOR TRIPS INVOLVING FUNDRAISING FOR THE CENTER. SOCIAL CLUB DUES ARE PAID FOR THE CENTER'S PRESIDENT & DIRECTOR AND VICE PRESIDENT OF DEVELOPMENT. NONE OF THESE ITEMS ARE CONSIDERED TAXABLE COMPENSATION TO THESE INDIVIDUALS. PART I, LINE 7 THE BONUS ARRANGEMENT FOR ALL OFFICERS, KEY EMPLOYEES AND HIGHLY COMPENSATED EMPLOYEES IS DISCRETIONARY AND ENTIRELY PERFORMANCE BASED. WASHINGTON HEALTH CARE FACILITIES AUTHORITY 911108929 2007-11-15 5200000 REIMBURSE THE CENTER FOR COSTS OF ACQUIRING REAL PROPERTY & IMPROVEMENTS 0 0 0 WASHINGTON HEALTH CARE FACILITIES AUTHORITY 911108929 93978E6G2 2009-11-24 15381009 REFUND BONDS ISSUED 11/1/2002 0 0 0 WASHINGTON HEALTH CARE FACILITIES AUTHORITY 911108929 93978E6G2 2009-11-24 8842608 REFUND BONDS ISSUED 11/1/2002 0 0 0 WASHINGTON HEALTH CARE FACILITIES AUTHORITY 911108929 93978E6G2 2009-11-24 32093411 REFUND BONDS ISSUED 11/1/2002 0 0 0 557339 5200000 35948 32182 5131870 2007 0 0 1 1 837034 15381009 1466385 169304 69174 13676147 2009 1 0 1 1 481214 8842608 843031 97333 39769 7862475 2009 1 0 1 1 1746522 32093411 3059701 353262 144336 28536111 2009 1 0 1 1 0 0 0 0 0.00000 0.00000 0.00000 1 0 0 0 0 0.00000 0.00000 0.00000 1 0 0 0 0 0.00000 0.00000 0.00000 1 0 0 0 0 0.00000 0.00000 0.00000 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X SCHEDULE K, PART I, BOND N DESCRIPTION OF PURPOSE TO REPAY A TAXABLE BRIDGE LOAN INCURRED BY THE CENTER TO ACQUIRE LAND AND THE 1100 EASTLAKE BUILDING IN SEATTLE, WASHINGTON. TO CONSTRUCT, REMODEL, RENOVATE AND EQUIP HEALTH CARE FACILITIES LOCATED AT THE 1100 EASTLAKE BUILDING AND AT THE CENTER'S EXISTING SOUTH LAKE UNION CAMPUS IN SEATTLE. TO CONSTRUCT A CONNECTION BETWEEN THE 1100 EASTLAKE BUILDING AND THE SOUTH LAKE UNION CAMPUS. SCHEDULE K, PART I THE BOND ISSUES LISTED IN PART I WITH CUSIP NUMBERS 93978E6G2 (ALL ROWS), 93978HCL7 (ALL ROWS), 93978HBT1 (ALL ROWS) AND 93978HBV6 (ROW A ONLY) ARE POST-DECEMBER 31, 2002 REFUNDING ISSUES WHICH REFUND PRE-JANUARY 1, 2003 BOND ISSUES AND ARE THEREFORE NOT INCLUDED IN PART III, PRIVATE BUSINESS USE. WASHINGTON HEALTH CARE FACILITIES AUTHORITY 911108929 93978E6G2 2009-11-24 18735275 REFUND BONDS ISSUED 11/1/2002 0 0 0 WASHINGTON HEALTH CARE FACILITIES AUTHORITY 911108929 93978E6G2 2009-11-24 39972686 REFUND BONDS ISSUED 11/15/2001 0 0 0 WASHINGTON HEALTH CARE FACILITIES AUTHORITY 911108929 2010-11-04 30000000 ACQUISITION OF A SIX-STORY OFFICE BUILDING 0 0 0 WASHINGTON HEALTH CARE FACILITIES AUTHORITY 911108929 93978HCL7 2011-06-30 49522564 REFUND BONDS ISSUED 11/15/2001 0 0 0 1019571 18735275 1786172 206225 84260 16658619 2009 1 0 1 1 1120659 39972686 3829025 627017 35516644 2009 1 0 1 1 840000 30000000 367238 416292 29216470 2010 1 0 1 1 298325 49522564 646773 29219 48846572 2011 0 0 1 1 0 0 0 0 0.00000 0.00000 0.00000 1 0 0 0 0 0.00000 0.00000 0.00000 1 0 0 1 1 0 0.00000 0.00500 0.00500 1 0 0 0 0 0.00000 0.00000 0.00000 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 WASHINGTON HEALTH CARE FACILITIES AUTHORITY 911108929 93978HCL7 2011-06-30 33478278 REFUND BONDS ISSUED 11/24/2009 0 0 0 WASHINGTON HEALTH CARE FACILITIES AUTHORITY 911108929 93978HBT1 2011-06-30 34532776 REFUND BONDS ISSUED 11/15/2001 0 0 0 WASHINGTON HEALTH CARE FACILITIES AUTHORITY 911108929 93978HBT1 2011-06-30 17411441 REFUND BONDS ISSUED 11/24/2009 0 0 0 WASHINGTON HEALTH CARE FACILITIES AUTHORITY 911108929 93978HBT1 2011-06-30 5580783 REFUND BONDS ISSUED 11/24/2009 0 0 0 201675 33478278 437232 19752 33021294 2011 1 0 1 1 34532776 285850 267781 33968689 10455 2011 1 0 1 1 17411441 144126 135016 17127028 5271 2011 1 0 1 1 5580783 46196 43276 5489622 1690 2011 1 0 1 1 0 0 0 0 0.00000 0.00000 0.00000 1 0 0 0 0 0.00000 0.00000 0.00000 1 0 0 0 0 0.00000 0.00000 0.00000 1 0 0 0 0 0.00000 0.00000 0.00000 1 0 0 0 0 0 0 0 1 1 BARCLAYS BANK PLC 16.500000000000 0 0 0 0 0 0 1 1 BARCLAYS BANK PLC 16.500000000000 0 0 0 0 0 0 1 1 BARCLAYS BANK PLC 16.500000000000 0 0 0 0 0 WASHINGTON HEALTH CARE FACILITIES AUTHORITY 911108929 93978HBV6 2011-06-30 352651 REFUND BONDS ISSUED 11/24/2009 0 0 0 WASHINGTON HEALTH CARE FACILITIES AUTHORITY 911108929 93978HBV6 2011-06-30 84147349 SEE PART VI 0 0 0 352651 1779 3653 346887 332 2011 1 0 1 1 84147349 3488245 424356 871651 60757763 18605334 2012 0 0 0 0 0 0 0 0 0.00000 0.00000 0.00000 1 0 0 0 0 0.00000 0.00000 0.00000 1 0 1 1 BARCLAYS BANK PLC 19.500000000000 0 0 0 0 0 0 1 1 BARCLAYS BANK PLC 19.500000000000 0 0 0 0 0 IKARIA INC ROBERT NELSEN ORGANIZATION TRUSTEE IS A DIRECTOR OF IKARIA 666296 DIVIDEND INCOME RECEIVED FROM INTERESTED PERSON 0 X 1 22000 APPRAISAL X 31 4661305 MARKET VALUE X EQUIPMENT 3 1132526 MARKET VALUE X PILLOWS 1 4900 MARKET VALUE X AUCTION ITEMS 308 440458 MARKET VALUE 1 0 1 0 METHOD FOR DETERMINING NUMBER OF CONTRIBUTORS: PART I, COLUMN (B): THE NUMBER IN PART I, COLUMN (B) REPRESENTS THE NUMBER OF CONTRIBUTIONS RECEIVED. FORM 990, PART VI, SECTION B, LINE 11 UNDER THE CENTER'S BYLAWS, THE FINANCE COMMITTEE IS RESPONSIBLE FOR REVIEWING AND INVESTIGATING FINANCIAL TRANSACTIONS OF FHCRC INCLUDING RESPONSIBILITY OF INTERNAL AND EXTERNAL AUDITING AND FOR MAKING RECOMMENDATIONS TO THE BOARD CONCERNING THESE MATTERS. FHCRC'S VICE PRESIDENT OF FINANCE & CHIEF FINANCIAL OFFICER AND HIS STAFF WORK CLOSELY WITH THE OUTSIDE ACCOUNTING FIRM FHCRC ENGAGES TO PREPARE THE FORM 990. THE DRAFT FORM 990 IS ALSO REVIEWED BY THE CORPORATE TREASURER, THE EXECUTIVE VICE PRESIDENT & CHIEF OPERATING OFFICER AND THE VICE PRESIDENT & GENERAL COUNSEL PRIOR TO PROVIDING IT TO THE FINANCE COMMITTEE. THE FINANCE COMMITTEE CONSULTS WITH THE CHIEF OPERATING OFFICER, CHIEF FINANCIAL OFFICER, GENERAL COUNSEL AND CORPORATE TREASURER AND SUCH OTHER PERSONS THE FINANCE COMMITTEE MAY DESIGNATE TO REVIEW THE DRAFT FORM 990. SUBSEQUENT TO ITS REVIEW, THE FINANCE COMMITTEE REPORTS TO THE BOARD REGARDING ITS OVERSIGHT OF FORM 990. THE FINAL DRAFT IS PROVIDED TO THE FULL BOARD PRIOR TO FILING THE RETURN. FORM 990, PART VI, SECTION B, LINE 12C THE EXECUTIVE COMMITTEE OF THE BOARD IS RESPONSIBLE FOR MONITORING CONFLICTS OF INTEREST INVOLVING TRUSTEES OR THE PRESIDENT & DIRECTOR OF THE CENTER. THE PRESIDENT & DIRECTOR OF THE CENTER IS RESPONSIBLE FOR MONITORING CONFLICTS OF INTEREST INVOLVING OTHER OFFICERS, SCIENTIFIC STAFF AND OTHER KEY PERSONNEL DESIGNATED BY THE PRESIDENT & DIRECTOR. UNDER THE FHCRC CONFLICT OF INTEREST POLICY AND RELATED GUIDELINES, AN ANNUAL CONFLICT OF INTEREST DISCLOSURE DOCUMENT AIMED AT DETERMINING FAMILY AND BUSINESS RELATIONSHIPS AND TRANSACTIONS THAT CONSTITUTE A CONFLICT OF INTEREST UNDER THE POLICY, IS DISTRIBUTED TO AND MUST BE COMPLETED BY ALL COVERED PERSONS. DISCLOSURES BY TRUSTEES AND THE PRESIDENT & DIRECTOR ARE REVIEWED BY THE OFFICE OF THE GENERAL COUNSEL WHO REPORTS ANY CONFLICTS TO THE EXECUTIVE COMMITTEE WITH RECOMMENDATIONS ON APPROPRIATE TERMS FOR A CONFLICT MANAGEMENT PLAN. CONFLICT MANAGEMENT PLANS FOR TRUSTEES AND THE PRESIDENT & DIRECTOR ARE REVIEWED AND APPROVED BY THE EXECUTIVE COMMITTEE AND SIGNED BY THE PERSON WITH THE CONFLICT OF INTEREST AND THE CHAIR OF THE BOARD. DISCLOSURE BY MEMBERS OF THE SCIENTIFIC STAFF, OFFICERS OTHER THAN THE PRESIDENT & DIRECTOR AND OTHER KEY PERSONNEL DESIGNATED BY THE PRESIDENT & DIRECTOR ARE REVIEWED BY THE OFFICE OF THE PRESIDENT & DIRECTOR, THE OFFICE OF THE GENERAL COUNSEL, AND THE DIRECTOR OF THE DIVISION IN WHICH THE PERSON HAS HIS OR HER PRIMARY APPOINTMENT OR RESPONSIBILITIES. IF A CONFLICT IS DETERMINED TO EXIST UNDER THE POLICY A WRITTEN CONFLICT MANAGEMENT PLAN IS RECOMMENDED BY THE OFFICE OF THE GENERAL COUNSEL AND APPROVED AND SIGNED BY THE OFFICE OF THE DIRECTOR, THE OFFICE OF THE GENERAL COUNSEL AND THE DIVISION DIRECTOR AS WELL AS THE PERSON WHO HAS THE CONFLICT. CONFLICT MANAGEMENT PLANS ARE DESIGNATED TO MANAGE, REDUCE AND ELIMINATE CONFLICTS TO PREVENT BIAS, IMPROPER INFLUENCE, OR MISUSE OF FHCRC OR GOVERNMENT RESOURCES. THE CONFLICT MANAGEMENT PLANS FOR TRUSTEES USUALLY REQUIRE THE AFFECTED TRUSTEE TO RECUSE HIMSELF OR HERSELF FROM VOTING ON ANY MATTERS INVOLVING THE AFFECTED TRANSACTION OR RELATIONSHIP ALTHOUGH HE OR SHE IS ALLOWED TO PROVIDE FACTUAL INFORMATION IF REQUESTED BY THE BOARD OF THE EXECUTIVE COMMITTEE. ALL TRANSACTIONS REQUIRING BOARD OR COMMITTEE APPROVAL MUST BE APPROVED BY A MAJORITY OF DISINTERESTED PERSONS. CONFLICT MANAGEMENT PLANS INVOLVING SCIENTIFIC STAFF, OFFICER OR OTHER KEY PERSONNEL USUALLY IMPOSE ONE OR MORE OF THE FOLLOWING CONDITIONS OR RESTRICTIONS: 1) PUBLIC DISCLOSURE OF THE INTEREST, 2) MONITORING OF RESEARCH BY INDEPENDENT REVIEWERS, 3) MODIFICATION OF THE RESEARCH PLAN, 4) DISQUALIFICATION FROM PARTICIPATION IN ALL OF OR A PORTION OF THE RESEARCH BY THE PERSON WITH THE CONFLICT OF INTEREST, 5) DIVESTURE OF THE INTEREST, 6) SEVERANCE OF THE RELATIONSHIP CREATING THE CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION FOR THE PRESIDENT & DIRECTOR IS DETERMINED AND APPROVED BY THE BOARD COMPENSATION COMMITTEE. THE COMPENSATION OF OTHER OFFICERS AND KEY PERSONNEL AT FHCRC IS DETERMINED BY THE PRESIDENT & DIRECTOR SUBJECT TO RATIFICATION BY THE COMPENSATION COMMITTEE. THE COMPENSATION COMMITTEE HAS DEVELOPED, CONSISTENT WITH THE ORGANIZATION'S PHILOSOPHY AND PRINCIPLES, GUIDELINES FOR DETERMINING COMPENSATION AND BENEFITS. THE COMPENSATION COMMITTEE ALSO HIRES A QUALIFIED INDEPENDENT COMPENSATION SPECIALIST ("INDEPENDENT EXPERT") EVERY TWO YEARS TO REVIEW, ANALYZE AND PROVIDE BENCHMARKING DATA FOR THE TOTAL COMPENSATION PACKAGES OF ALL OFFICERS AND KEY EMPLOYEES. APPROPRIATE COMPARABILITY DATA IS OBTAINED FROM THE INDEPENDENT EXPERT. NO PERSON WITH A CONFLICT OF INTEREST MAY PARTICIPATE IN DETERMINING OR APPROVING ANY EXECUTIVE COMPENSATION. MEETINGS OF THE COMPENSATION COMMITTEE ARE DOCUMENTED IN MINUTES WHICH ARE APPROVED AT THE NEXT COMMITTEE MEETING. THE ABOVE PROCESS WAS LAST UNDERTAKEN IN 2012. FORM 990, PART VI, SECTION C, LINE 19 WHILE FEDERAL TAX LAWS DO NOT MANDATE THAT THE ORGANIZATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS BE MADE AVAILABLE FOR PUBLIC INSPECTION, THE ORGANIZATION MAKES THESE DOCUMENTS AVAILABLE UPON REQUEST. CHANGES IN NET ASSETS OR FUND BALANCES: FORM 990, PART XI, LINE 5: NET UNREALIZED LOSSES ON INVESTMENTS: -25,915,220. ADJUSTMENT FOR DECONSOLIDATION OF CONTROLLED AFFLIATE (SVRF) -434,077. TOTAL TO FORM 990, PART XI, LINE 5: -26,349,297. SEATTLE VACCINE RESEARCH FUND 1100 FAIRVIEW AVENUE NORTH SEATTLE WA 98109 331111221 ANTI-RETROVITAL THERAPY FOR ELIGIBLE PARTICIPANTS WA 501(C)(3) LINE 11A, I FRED HUTCHINSON CANCER RESEARCH CENTER 1 UPCID LTD POB 3935 MULAGO HOSPITAL UPPER MU KAMPALA UG RESEARCH AND EDUCATION ON CANCER AND INFECTIOUS DISEASES UG FRED HUTCHINSON CANCER RESEARCH CENTER 1 HUTCHINSON CANCER RESEARCH INSTITUTE OF SOUTH AFRICA 6TH FLOOR 119 HERTZOG BLVD FORESHORE, CAPETOWN SF 8001 RESEARCH SF FRED HUTCHINSON CANCER RESEARCH CENTER 1 CHARITABLE REMAINDER TRUSTS (5) 1100 FAIRVIEW AVE NORTH SEATTLE WA 981091024 INVESTMENT WA FRED HUTCHINSON CANCER RESEARCH CENTER T 0 0 0 0 0 0 0 0 0 0 1 1 0 0 1 0 1 0 UPCID LTD K 485217 BASED ON SPECIFIC COST CENTERS UPCID LTD O 540468 CIP COSTS INCURRED BY FH FOR UPCI UPCID LTD Q 425542 CASH TRANSFERS/ADVANCES TO UPCID UPCID LTD L 474321 PAYMENTS FOR RESEARCH SERVICES